Document:

EX-10.10 LICENSE AGREEMENT

 

EXHIBIT 10.10

*Certain portions of this exhibit have been omitted pursuant to a request for confidential

treatment which has been filed separately with the SEC.

License Agreement

between

Vanderbilt University

and

Cumberland Pharmaceuticals Inc.

May 1999

 

 

LICENSE AGREEMENT

between

VANDERBILT UNIVERSITY

and

CUMBERLAND PHARMACEUTICALS INC.

THIS AGREEMENT, by and between VANDERBILT UNIVERSITY, a not-for-profit corporation, organized and
existing under the laws of the state of Tennessee (“VANDERBILT”), and Cumberland Pharmaceuticals
Inc., a Tennessee corporation, having a principal place of business at Nashville, Tennessee (the
“LICENSEE”) is effective as of the 28TH day of  May , 1999 (the
“EFFECTIVE DATE”).

RECITALS

WHEREAS, VANDERBILT represents that it holds title, by assignment, to the data, including patient
records, created by Gordon R. Bernard, M.D., Professor of Medicine (“the Data”) relating to
intravenously administered ibuprofen for treatment of sepsis and that it has all rights to the Data
and VANDERBILT is willing to grant a license to the Data and any intellectual property rights
associated therewith; and

WHEREAS, LICENSEE desires to acquire, and VANDERBILT desires to grant to LICENSEE, an exclusive,
worldwide license to use the Data in connection with the development and production of the
“Product,” as hereinafter defined, for which LICENSEE intends to seek necessary approvals from
regulatory governmental agencies in order to market and sell such products upon the terms and
conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, it is
agreed by the parties as follows:

1. DEFINITIONS

1.1 Product(s) shall mean a pharmaceutical product, consisting, in whole or part, of
intravenously administered ibuprofen manufactured by or for LICENSEE based on the Data and approved
by a regulatory agency for sale or other distribution in the country in which the agency has
regulatory authority.

1.2 Net Sales. The term “Net Sales” shall mean the receipts for Products sold by LICENSEE
or a sublicense during the term of this Agreement, computed quarter by quarter, less allowances
for:

          (a) cash, trade, or quantity discounts and rebates,

          (b) taxes, including sales taxes and duties,

          (c) credits, returns and replacements, and

          (d) shipping and insurance charges.

     Products shall be deemed sold when paid for.

1

 

1.3 The Inventor. The term “Inventor” shall mean Gordon R. Bernard, M.D., Professor of
Medicine.

1.4 Affiliate means, when used with reference to LICENSEE, any entity directly or
indirectly controlling, controlled by or under common control with LICENSEE. For purposes of this
Agreement, “control” means the direct or indirect ownership of over fifty percent (50%) of the
outstanding voting securities of an entity, or the right to receive over fifty percent (50%) of the
profits or earnings of an entity, or the right to control the policy decisions of an entity.

2. GRANT

2.0 Exclusive License. VANDERBILT hereby grants to LICENSEE and LICENSEE hereby accepts
from VANDERBILT, upon the terms and conditions herein specified, an exclusive, royalty bearing,
worldwide license, with the right to sublicense, to use Data for any purpose, including manufacture
and sale of the Product(s) as well as submission to regulatory governmental agencies for approval
to sell Product(s), except as otherwise expressly set forth herein. Upon execution of this
Agreement, VANDERBILT through Gordon Bernard will promptly deliver to LICENSEE all information and
data relating to intravenously administered ibuprofen to which VANDERBILT holds title.

2.1 Federal Government Rights Reserved. Notwithstanding the exclusive license granted
herein, the Federal Government shall receive all the rights, if any, to the Data required by law or
regulation to be reserved to the government. All rights granted in this Agreement are expressly
granted subject to the rights of the Federal Government and such rights are specifically reserved
to the Government by this Agreement.

2.2 Reservation of Right. VANDERBILT reserves the right to make, use and further develop
the Data for its own non-commercial, educational and research purposes.

2.3 Upon receipt of regulatory approval to sell the Product, LICENSEE shall use reasonable efforts
to effect introduction of the Products into the commercial market as soon as practicable,
consistent with sound and reasonable business practices and judgment; thereafter, until the
expiration of this Agreement, LICENSEE shall use commercially reasonable efforts to keep Products
reasonably available to the public.

2.4 Subsidiaries and Distributors. License rights granted hereunder shall enable LICENSEE
to make, use, sell or otherwise distribute Product through any of its subsidiaries and to sell
Product through any of its normal channels including its subsidiaries, distributors, and agents.

2

 

3. TERMS AND TERMINATION

3.0 Term. Unless previously terminated as herein provided, this Agreement shall become
effective as stated above and shall continue until LICENSEE ceases distribution of Product in all
countries in which it has obtained regulatory approval for manufacture and distribution of such
product based on use of the Data.

3.1 Termination. This Agreement may be terminated by written notice to the other party:

     (a) Other than as stated in Article 3.1(b), in the event that one party commits any
substantial breach of this Agreement, the non-breaching party at its option, may terminate this
Agreement by giving the breaching party written notice pursuant to Article 10.2 of its election to
terminate as of a stated date, not less than forty-five (45) days from the date of the notice.
Such notice shall state the nature of the defaults claimed by the non-breaching party. The
breaching party during said forty-five (45) day period, or such longer period as may be indicated
by the other, may correct any default stated in said notice and if such default is corrected, this
Agreement shall continue in full force and effect as if such notice had not been given. Failure by
LICENSEE to pay earned royalties to VANDERBILT in a timely manner shall be deemed a substantial
breach of the Agreement.

     (b) In the event LICENSEE shall file a petition for voluntary bankruptcy, has a petition for
involuntary bankruptcy filed against it (which petition is not withdrawn within sixty (60) days of
such filing), is adjudicated to be bankrupt, or shall make an assignment for the benefit of
creditors, or shall apply for or consent to the appointment of a receiver or trustee of a
substantial part of its property, to the extent permitted by law, this Agreement shall
automatically terminate effective as of a date ten (10) days prior to LICENSEE’s change of status
hereunder and shall be subject to Article 3.2.

     (c) In the event a LICENSEE provides written notice to VANDERBILT and LICENSEE is terminating
pursuing regulatory approval for the Product.

3.2 Effect of Termination. Upon termination of this Agreement, LICENSEE shall cease all
production and sale of Product except for the production and sale of Product on which production
had begun prior to notice of such termination. LICENSEE may continue to sell such Product for up
to one year after such notice upon payment of royalties accruing thereon, and shall render an
accounting to VANDERBILT of any royalties which may be due. Immediately upon termination all
rights of Licensee, except as expressly stated in this article, shall revert to VANDERBILT.

3.3 Sections 3.2, 3.4, 5.1, Article 6, Article 7, Article 8, Article 9, and Section 10.8 of the
agreement shall survive termination.

3

 

4. CONSULTING AGREEMENTS

4.0 Consulting Agreements. In the event LICENSEE desires to have a Consulting Agreement
with Dr. Bernard, any such Consulting Agreement will be separate and apart from this Agreement, and
in accord with VANDERBILT policy and procedures.

5.
ROYALTIES AND MILESTONES

5.0 Initial Payment. Upon execution of this Agreement, LICENSEE agrees to grant VANDERBILT
25,000 shares of common stock in Cumberland Pharmaceuticals, Inc. (the “Stock”) upon the same terms
and conditions contained in Section 2.2 of the subscription agreement attached to the LICENSEE’s
Confidential Private Placement Memorandum dated January 29, 1999. A certificate for such Stock will
be delivered to VANDERBILT within ten (10) days of the effective date of this Agreement as set
forth above.

5.1 Royalties. Commencing on the effective date of this Agreement, LICENSEE agrees to pay
VANDERBILT at the rate of [***] percent of Net Sales of Products sold to third parties.

5.2 Schedule of Payment. LICENSEE further agrees to pay royalties on a quarterly basis
based on LICENSEE’s fiscal quarter and payments shall be due within forty-five (45) days after the
completion of the fiscal quarter. Each such payment shall be accompanied by a statement for the
period covered by such royalties showing total number or volume of Products sold, and total
royalties due, and identified as Net Sales within U.S. or non-U.S. This statement is to be
certified as accurate by a responsible officer of LICENSEE.

5.3 Milestone Payments. LICENSEE agrees to use its commercially reasonable best efforts and
diligence to proceed with the development, manufacture, use and sale of Products. Within thirty
(30) days following notification of marketing approval granted by the U.S. Food and Drug
Administration for distribution of the Product (“FDA Notification”), LICENSEE agrees to grant
VANDERBILT Stock with a value of $150,000, as measured by the offering price per share of Stock
offered by the Company to outside investors (i) at the time that such grant is due, or in the event
that no such offering is ongoing at the time such grant is required, (ii) at such earlier date when
LICENSEE last sold Stock to such investors prior to FDA Notification. A certificate for such Stock
will be delivered to VANDERBILT within thirty (30) days following FDA Notification.

5.4 Reports. LICENSEE shall provide written annual reports within [***] after December 31
of each calendar year which shall include but not be limited to: reports of progress on research
and development, regulatory approvals, manufacturing, marketing and sales during the preceding
twelve (12) months as well as plans for the coming year. LICENSEE shall promptly notify VANDERBILT
if any changes in the marketplace or in LICENSEE’s financial condition or business aims suggest
commercialization will not occur within three (3) years from the date hereof.

5.5 Records. LICENSEE shall maintain complete and accurate records sufficient to enable
accurate calculation of royalties due VANDERBILT under this Agreement. LICENSEE shall, at
VANDERBILT’s request and expense, provide certified statements from LICENSEE’s auditors, concerning
royalties due pursuant to this Agreement. Once a calendar year, VANDERBILT shall have the right to
select a certified public accountant to inspect, on reasonable notice and during regular business
hours, the records of LICENSEE to verify LICENSEE’s statements and royalty payments pursuant to
this Agreement. The entire cost for such inspection shall be borne by VANDERBILT, unless there is
a discrepancy greater than 5% in VANDERBILT’s favor, in which case LICENSEE shall bear the entire
cost of the inspection. Records shall be preserved by LICENSEE for three (3) years for inspection
by VANDERBILT.

5.6 If this Agreement is not terminated in accordance with other provisions hereof, LICENSEE’s
obligation to pay royalties hereunder shall continue as long as Product is being distributed by
LICENSEE.

4

 

5.7 The royalty on sales in currencies other than U.S. Dollars shall be calculated using the
appropriate exchange rate for such transactions quoted by CITICORP BANK (NEW YORK) foreign exchange
desk on the last banking day of each calendar quarter. Royalty payments to VANDERBILT shall be in
U.S. Dollars.

5.8 In the event that LICENSEE is acquired by a third party or enters into a joint venture with a
third party, or in any other way transfers all of its assets, including this License to a third
party, all obligations of this License, including the foregoing royalty terms, shall be binding
upon the party acquiring this License.

6. CONFIDENTIALITY

6.0 It may be necessary for one party to disclose to the other party certain confidential or
proprietary information, including business plans and marketing strategies. In such event, the
receiving party agrees to preserve such identified information as confidential. The obligation of
confidentiality shall not apply to information which:

     (a) is now in the public domain or which becomes generally available to the public through no
fault of the receiving party; or

     (b) is already known to, or in the possession of, the receiving party prior to disclosure by
the disclosing party as can be demonstrated by documentary evidence; or

     (c) is disclosed on a non-confidential basis from a third party having the right to make such
a disclosure; or

     (d) is independently developed by the receiving party as can be demonstrated by documentary
evidence.

6.1 Term. The confidentiality obligations of this Article shall continue for a period of
five (5) years beyond the termination of this Agreement.

5

 

7. INFRINGEMENT

7.0 Products Infringing Third Parties. Each party shall promptly notify the other if any
legal proceedings are commenced or threatened against either party or any purchaser of a Product
sold by LICENSEE on the ground that the manufacture, use, sale or possession of the Product is an
infringement of a third party’s patent or other intellectual property rights. LICENSEE shall, at
its own expense, conduct all suits brought against it as a result of the exercise of the rights
granted hereunder, and VANDERBILT shall, at the request and expense of LICENSEE, give LICENSEE all
reasonable assistance in any such proceedings. Payment of any amounts which may be recovered by
such third party by way of judgment, award, decree, or settlement that resulted from infringement
of third party patent rights or other rights by a Product, including attorneys’ fees and other
costs shall be the sole responsibility of LICENSEE. LICENSEE agrees not to settle or compromise any
action, suit or proceeding without the consent of VANDERBILT.

8. WARRANTIES AND INDEMNITIES

8.0 Nothing in this Agreement shall be constructed as:

     (a) a warranty or representation by VANDERBILT that anything made, used, sold, or otherwise
disposed of through the license granted herein is or will be free from infringement of patents
rights of third parties;

     (b) an obligation by VANDERBILT to bring or prosecute actions or suits against third parties
for infringement;

     (c) Granting by implication, estoppel, or otherwise any licenses under patents of VANDERBILT.

8.1 To the best of its knowledge and belief, VANDERBILT hereby represents and warrants that it is
the sole owner of the Data and has the right to grant the license to the Data provided herein and
that to the best of its knowledge and belief after due inquiry, no rights of patients or other
persons are or will be infringed by the license granted to LICENSEE. VANDERBILT further represents
and warrants that the Data is both accurate and complete and includes all information and data
relating to intravenously administered ibuprofen to which VANDERBILT holds title. VANDERBILT also
represents and warrants that it has full right, title, and authority to enter into this Agreement
and that VANDERBILT is not under any obligation resulting from any contract or arrangement, to any
person, firm, or corporation, which is inconsistent or in conflict with this Agreement.

8.2 (a) LICENSEE shall indemnify, defend and hold harmless VANDERBILT and its trustees, officers,
faculty, staff, employees, students, agents and representatives, and their respective successors,
heirs and assigns (the “Indemnities”), against any liability, damage, loss or expenses (including
reasonable attorneys’ fees and expense of litigation) incurred by or imposed upon the Indemnities
or any one of them in connection with any claims, suits, actions, demands, or judgments arising out
of any theory of law (including, but not limited

6

 

to, actions in the form of tort, warranty, or strict liability) arising from LICENSEE’s use of the
Data pursuant to any right or license granted under this Agreement. Such indemnity obligation
shall include claims and expenses related to infringement of a third party’s rights by the Product.

     (b) LICENSEE agrees, at its own expense, to provide attorneys reasonably acceptable to
VANDERBILT to defend against any actions brought or filed against any party indemnified hereunder
with respect to the subject of indemnity contained herein, whether or not such actions are
rightfully brought.

     (c) VANDERBILT shall indemnify, defend and hold harmless LICENSEE and its officers, directors,
employees, agents, and shareholders, notwithstanding termination of this Agreement, against any
liability, damage, loss, or expenses (including reasonable attorney’s fees) incurred by or imposed
in connection with any claims, suits, actions, demands or judgments arising out of any theory of
law (including, but not limited to, actions in the form of tort, warranty, or strict liability)
arising from default under any provision of this Agreement by VANDERBILT.

8.3 VANDERBILT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND EXPRESS OR IMPLIED,
OTHER THAN AS EXPRESSLY STATED HEREIN. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT USE OF A PRODUCT WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

8.4 Regarding the indemnity and hold harmless provisions, under Paragraph 8.2, VANDERBILT shall
give prompt written notice to LICENSEE of the commencement of any action, suit, or proceeding for
which indemnification may be sought, and LICENSEE, through counsel reasonably satisfactory to
VANDERBILT shall assume the defense thereof; provided, however, that VANDERBILT shall be entitled
to participate in any such action, suit, or proceeding with counsel of its own choice, but at its
own expense. If LICENSEE fails to assume the defense within ninety (90) days of receipt of written
notice of the action, suit, or proceeding, VANDERBILT may assume such defense and the reasonable
fees and expenses of its attorneys will be covered by the indemnity provided for in Paragraph 8.2.
No such action, suit, or proceeding shall be compromised or settled in any manner which might
adversely affect the interests of VANDERBILT without the prior written consent of VANDERBILT.
Notwithstanding anything in this Paragraph to the contrary, LICENSEE shall not, without the written
consent of VANDERBILT, which consent shall not be unreasonably withheld:

     (a) Settle or compromise any action, suit, or proceeding or consent to the entry of any
judgment which does not include as an unconditional term thereof the delivery by the claimant or
plaintiff to VANDERBILT of a written release from all liability in respect of such action, suit, or
proceeding; or

     (b) Settle or compromise any action, suit, or proceeding in any manner which may adversely
affect VANDERBILT.

7

 

8.5 Insurance. (a) Beginning at the time as any Product is being commercially distributed
or sold by LICENSEE or agent of LICENSEE, LICENSEE or such other, shall make commercially
reasonable efforts to procure and maintain comprehensive general product liability and tort
liability insurance in amounts not less than $5,000,000 per incident and $5,000,000 annual
aggregate and name the Indemnities as additional insureds. Such comprehensive general liability
insurance shall provide (i) product liability coverage and (ii) broad form contractual liability
coverage for LICENSEE’s indemnification under this Agreement. If LICENSEE elects to self-insure or
otherwise finds it necessary to self-insure all or part of the limits described above, such
self-insurance program must be reasonably acceptable to VANDERBILT. LICENSEE agrees that no amount
greater than the sum of $250,000 shall be deductible under LICENSEE’s primary coverage for
VANDERBILT and LICENSEE against any claims or suits arising from alleged defects in Products. The
minimum amounts of insurance coverage required shall not be construed to create or limit LICENSEE’s
liability with respect to its indemnification under this Agreement.

     (b) LICENSEE represents and warrants that it will make commercially reasonable efforts to
acquire its product liability and general tort liability is of the occurrence-based rather than
claims-made type. Within thirty (30) day after the date of the first commercial sale of a Product
hereunder, LICENSEE shall provide VANDERBILT with a certificate or certificates of insurance
evidencing that VANDERBILT has been named as an additional insured party and evidencing the
insurer(s) is required to notify VANDERBILT in writing at least thirty (30) days in advance of any
termination of the policy or certificate, or any modification that would cause LICENSEE no longer
to be in compliance with the provisions of this Article, or would cause the representation and
warranties set forth above in this Article no longer to be true, such written notification to
specify the reason for such termination, the nature of the proposed modification, as the case may
be. It is expressly agreed by the parties that the provisions of this Article regarding insurance
shall in no way limit LICENSEE’s indemnity obligations, except to the extent that LICENSEE’s
insurer(s) actually pays VANDERBILT amounts for which VANDERBILT is entitled to be indemnified
under this Agreement, nor shall VANDERBILT have any obligation to pursue any insurer as a
precondition to its rights to be indemnified by LICENSEE. As used in this Article, the term
“VANDERBILT” shall include VANDERBILT, and its officers, directors, agents and employees. If
LICENSEE does not make commercially reasonable efforts to obtain replacement insurance within such
thirty (30) day period specified above, VANDERBILT shall have the right to terminate this Agreement
effective at the end of such thirty (30) day period without notice or any additional waiting
periods.

     (c) LICENSEE shall maintain such comprehensive general product liability and tort liability
insurance or self-insurance beyond the expiration or termination of this Agreement during (i) the
period that any product relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold by LICENSEE or agent of LICENSEE and (ii) a period not less than the statute of
limitations for product liability claims in the state in which the product is being used.

8

 

9. USE OF VANDERBILT’S NAME

9.0 LICENSEE agrees not to identify VANDERBILT or to use the name of VANDERBILT, its faculty,
employees, or students, or any trademark, service mark, trade name, or symbol of VANDERBILT, or
that is associated with any of them, in promotional advertising or other similar materials without
VANDERBILT’s written consent, except as required by governmental authority. LICENSEE may, without
prior consent, refer to VANDERBILT as LICENSOR of the Data submitted in support of marketing
approval for Product in a business plan, fund raising material or the like. All other uses of
VANDERBILT’s name shall be made only after prior approval.

9.1 VANDERBILT agrees not to identify LICENSEE or to use the name of LICENSEE’s officers,
employees, or any trademark, service mark, trade name or symbol of LICENSEE without the written
consent of LICENSEE, except as may be required by governmental authority or as necessary in the
normal course of VANDERBILT’S business operations.

10. TERMS AND CONDITIONS

10. Manner of Payment. All payments hereunder shall be made by check to VANDERBILT. Where
required to do so by applicable law or treaty, LICENSEE shall withhold taxes required to be paid
to a taxing authority on account of such income to VANDERBILT, and LICENSEE shall furnish
VANDERBILT with satisfactory evidence of such withholding and payment in order to permit
VANDERBILT to obtain a tax credit or other relief as may be available under the applicable law or
treaty.

10.1 Provisions Contrary to Law. In performing this Agreement, the parties shall comply
with all applicable laws and regulations. In particular, it is understood and acknowledged that
the transfer of certain commodities and technical data is subject to United States laws and
regulations controlling the export of such commodities and technical data, including all Export
Administration Regulations of the United States Department of Commerce. These laws and regulations
among other things, prohibit or require a license for the export of certain types of technical
data to certain specified countries. LICENSEE hereby agrees and gives written assurance that it
will comply with all United States laws and regulations controlling the export of commodities and
technical data, that it will be solely responsible for any violation of such by LICENSEE or its
Affiliates, and that it will defend and hold VANDERBILT harmless in the event of any legal action
of any nature occasioned by such violation.

Nothing in this Agreement shall be construed so as to require the violation of any law, and
wherever there is any conflict between any provision of this Agreement and any law the law shall
prevail, but in such event the affected provision of this Agreement shall be affected only to the
extent necessary to bring it within the applicable law.

10.2 Notices. Any notice may be initially given by facsimile with confirmation required or
permitted to be given by this License by postpaid, first class, registered or certified mail
addressed as set forth below unless changed by notice so given:

9

 

	 	 	 
	For LICENSEE:

	 	For VANDERBILT:
	 
	 	 
	Cumberland Pharmaceuticals Inc.

	 	Office of Technology Transfer
	209 10th Ave. South, Suite 332

	 	VANDERBILT University
	Nashville, Tennessee 37203

	 	1207 17th Avenue, S., Suite 210
	Fax: 615-259-9085

	 	Nashville, TN 37212
	 

	 	Fax: 615-343-4419
	 
	 	 
	With a copy to:
	 	 
	 
	 	 
	Stokes & Bartholomew, P.A.
	 	 
	424 Church Street, 28th Floor
	 	 
	Nashville, Tennessee 37214
	 	 
	Attn: Martin S. Brown, Esq.
	 	 
	Fax: 615-259-1470
	 	 

Such notice shall be effective upon receipt by the party to whom notice is sent.

10.3 Dispute Resolution. The parties acknowledge and agree that they have entered into this
agreement with the expectation of a long-term, mutually beneficial relationship. However, should
disagreement arise regarding obligations imposed on the parties be this Agreement, it is agreed
that the parties will, in good faith, promptly attempt to reach an amicable resolution of such
disagreement.

10.4 Force Majeure. Neither party to this License Agreement shall be liable for delay or
failure in the performance of any of its obligations hereunder if such delay or failure is due to
causes beyond its reasonable control, including, without limitation, acts of God, fires,
earthquakes, strikes, and labor disputes, acts of was, civil unrest, or intervention of any
governmental authority, but any such delay or failure shall be remedied by such party as soon as is
reasonably possible. Failure to make timely royalty payments shall not be excused by Force
Majeure.

10.5 Assignments. Except in connection with the sale of all or substantially all of the
assets of either party, this Agreement may not be assigned by either party without the prior
written consent of the other party, which consent shall not be unreasonably withheld. The parties
hereto agree that each is acting as an independent contractor and not as an agent of the other or
as joint ventures.

10.6 Waivers and Modifications. The failure of any party to insist on the performance of
any obligation hereunder shall not act as a waiver of such obligation. No waiver, modification,
release, or amendment of any obligation under this Agreement shall be valid or effective unless in
writing and signed by both parties hereto.

10.7 Successors in Interest. This Agreement shall inure to the benefit of and be binding on
the parties’ permitted assigns, successors in interest, and subsidiaries.

10

 

10.8 Choice of Law and Jurisdiction. This Agreement is subject to and shall be construed
and enforced in accordance with the laws of the U.S.A., and Tennessee. Any action on any dispute
arising out of this Agreement shall be tried in Davidson County, and the parties consent to the
jurisdiction of the state and federal courts there.

10.9 Entire Agreement. This Agreement constitutes the entire agreement between the parties
as to the subject matter hereof, and all prior negotiations, representations, agreements and
understandings are merged into, extinguished by and completely expressed by this Agreement.

11

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement on the date(s) written below.

	 	 	 	 	 	 	 	 	 	 	 
	LICENSEE	 	 	 	VANDERBILT UNIVERSITY	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ A.J. Kazimi
	 	 	 	By:
	 	/s/ Larry R. Steranka
	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	A.J. Kazimi
	 	 	 	 	 	Larry R. Steranka, Ph.D.	 	 
	Title:

	 	President
	 	 	 	Title:
	 	Director, Office of Technology Transfer	 	 
	Date:

	 	May 28, 1999
	 	 	 	Date:
	 	June 4, 1999	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	ACKNOWLEDGED AND AGREED	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gordon R. Bernard, M.D.	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	A.J. Kazimi	 	 	 	 	 	 	 	 
	Title:

	 	Professor of Medicine	 	 	 	 	 	 	 	 
	Date:

	 	6/2/99	 	 	 	 	 	 	 	 

12Ex-10.16.1

 

EXHIBIT 10.16.1

*Certain portions of this exhibit have been omitted pursuant to a request for confidential

treatment which has been filed separately with the SEC.

 

 

SECOND AMENDED AND RESTATED

LOAN AGREEMENT

April 6, 2006

by and between

CUMBERLAND PHARMACEUTICALS, INC.,

as the Borrower

and

BANK OF AMERICA, N.A.,

as the Bank

 

$ 9,500,000

 

 

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	1.	 	FACILITY NO. 1: LINE OF CREDIT AMOUNT AND TERMS	 	 	1	 
	 
	 	1.1	 	Line of Credit Amount	 	 	1	 
	 
	 	1.2	 	Availability Period	 	 	1	 
	 
	 	1.3	 	Borrowing Base	 	 	1	 
	 
	 	1.4	 	Interest Rate	 	 	3	 
	 
	 	1.5	 	Repayment Terms	 	 	4	 
	 
	 	 	 	 	 	 	 	 
	2.	 	FACILITY NO. 2: FIXED RATE TERM LOAN AMOUNT AND TERMS	 	 	4	 
	 
	 	2.1	 	Loan Amount	 	 	4	 
	 
	 	2.2	 	Availability Period	 	 	4	 
	 
	 	2.3	 	Interest Rate	 	 	4	 
	 
	 	2.4	 	Repayment Terms	 	 	4	 
	 
	 	2.5	 	Prepayments	 	 	5	 
	 
	 	 	 	 	 	 	 	 
	3.	 	FEES AND EXPENSES	 	 	5	 
	 
	 	3.1	 	Fees	 	 	5	 
	 
	 	3.2	 	Expenses	 	 	5	 
	 
	 	3.3	 	Reimbursement Costs	 	 	5	 
	 
	 	 	 	 	 	 	 	 
	4.	 	COLLATERAL	 	 	5	 
	 
	 	4.1	 	Personal Property	 	 	5	 
	 
	 	 	 	 	 	 	 	 
	5.	 	DISBURSEMENTS, PAYMENTS AND COSTS	 	 	6	 
	 
	 	5.1	 	Disbursements and Payments	 	 	6	 
	 
	 	5.2	 	Telephone and Telefax Authorization	 	 	6	 
	 
	 	5.3	 	Direct Debit (Pre-Billing)	 	 	6	 
	 
	 	5.4	 	Banking Days	 	 	7	 
	 
	 	5.5	 	Interest Calculation	 	 	7	 
	 
	 	5.6	 	Default Rate	 	 	7	 
	 
	 	 	 	 	 	 	 	 
	6.	 	CONDITIONS	 	 	7	 
	 
	 	6.1	 	Authorizations and Incumbency	 	 	8	 
	 
	 	6.2	 	Governing Documents	 	 	8	 
	 
	 	6.3	 	CET Intercompany Debt	 	 	8	 
	 
	 	6.4	 	Security Agreements	 	 	8	 
	 
	 	6.5	 	Perfection and Evidence of Priority	 	 	8	 
	 
	 	6.6	 	Payment of Fees	 	 	8	 
	 
	 	6.7	 	Good Standing	 	 	8	 
	 
	 	6.8	 	Legal Opinion	 	 	8	 
	 
	 	6.9	 	Warrant	 	 	8	 
	 
	 	6.10	 	Financial Statements	 	 	9	 
	 
	 	6.11	 	Insurance	 	 	9	 
	 
	 	6.12	 	Product Agreements	 	 	9	 
	 
	 	6.13	 	Consents, Licenses, Permits, Assignments	 	 	9	 
	 
	 	6.14	 	Availability	 	 	9	 
	 
	 	6.15	 	Representations, Warranties and No Default	 	 	9	 
	 
	 	6.16	 	Other Required Documentation	 	 	9	 
	 
	 	 	 	 	 	 	 	 
	7.	 	REPRESENTATIONS AND WARRANTIES	 	 	10	 
	 
	 	7.1	 	Formation	 	 	10	 
	 
	 	7.2	 	Authorization	 	 	10	 
	 
	 	7.3	 	Enforceable Agreement	 	 	10	 
	 
	 	7.4	 	Good Standing	 	 	10	 

i

 

	 	 	 	 	 	 	 	 	 
	 
	 	7.5	 	No Conflicts	 	 	10	 
	 
	 	7.6	 	Financial Information	 	 	10	 
	 
	 	7.7	 	Lawsuits	 	 	10	 
	 
	 	7.8	 	Collateral	 	 	10	 
	 
	 	7.9	 	Permits, Franchises	 	 	11	 
	 
	 	7.10	 	Other Obligations	 	 	11	 
	 
	 	7.11	 	Tax Matters	 	 	11	 
	 
	 	7.12	 	No Event of Default	 	 	11	 
	 
	 	7.13	 	Insurance	 	 	11	 
	 
	 	7.14	 	Location of Borrower	 	 	11	 
	 
	 	7.15	 	Capitalization	 	 	11	 
	 
	 	7.16	 	Material Adverse Change	 	 	11	 
	 
	 	 	 	 	 	 	 	 
	8.	 	COVENANTS	 	 	11	 
	 
	 	8.1	 	Use of Proceeds	 	 	12	 
	 
	 	8.2	 	Financial Information and Appraisal	 	 	12	 
	 
	 	8.3	 	Funded Debt to EBITDA Ratio	 	 	13	 
	 
	 	8.4	 	Minimum Fixed Charge Coverage Ratio	 	 	13	 
	 
	 	8.5	 	Minimum Net Worth	 	 	14	 
	 
	 	8.6	 	Minimum EBITDA	 	 	14	 
	 
	 	8.7	 	Capital Expenditures	 	 	14	 
	 
	 	8.8	 	Lease Expenditures	 	 	14	 
	 
	 	8.9	 	Dividends and Distributions	 	 	14	 
	 
	 	8.10	 	Bank as Principal Depository	 	 	14	 
	 
	 	8.11	 	Other Debts	 	 	14	 
	 
	 	8.12	 	Other Liens	 	 	15	 
	 
	 	8.13	 	Maintenance of Assets	 	 	15	 
	 
	 	8.14	 	Investments	 	 	15	 
	 
	 	8.15	 	Loans	 	 	15	 
	 
	 	8.16	 	Change of Management	 	 	16	 
	 
	 	8.17	 	Change of Ownership or Control	 	 	16	 
	 
	 	8.18	 	Additional Negative Covenants	 	 	16	 
	 
	 	8.19	 	Notices to Bank	 	 	16	 
	 
	 	8.20	 	Insurance	 	 	17	 
	 
	 	8.21	 	Compliance with Laws	 	 	17	 
	 
	 	8.22	 	ERISA Plans	 	 	17	 
	 
	 	8.23	 	Books and Records	 	 	17	 
	 
	 	8.24	 	Audits	 	 	18	 
	 
	 	8.25	 	Perfection of Liens	 	 	18	 
	 
	 	8.26	 	Cooperation	 	 	18	 
	 
	 	8.27	 	Collateral Account Notification and Acknowledgement	 	 	18	 
	 
	 	 	 	 	 	 	 	 
	9.	 	HAZARDOUS SUBSTANCES	 	 	18	 
	 
	 	9.1	 	Indemnity Regarding Hazardous Substances	 	 	18	 
	 
	 	9.2	 	Compliance Regarding Hazardous Substances	 	 	18	 
	 
	 	9.3	 	Notices Regarding Hazardous Substances	 	 	18	 
	 
	 	9.4	 	Site Visits, Observations and Testing	 	 	18	 
	 
	 	9.5	 	Definition of Hazardous Substances	 	 	19	 
	 
	 	9.6	 	Continuing Obligation	 	 	19	 
	 
	 	 	 	 	 	 	 	 
	10.	 	DEFAULT AND REMEDIES	 	 	19	 
	 
	 	10.1	 	Failure to Pay	 	 	19	 
	 
	 	10.2	 	Other Bank Agreements	 	 	19	 
	 
	 	10.3	 	Cross-Default	 	 	20	 
	 
	 	10.4	 	False Information	 	 	20	 
	 
	 	10.5	 	Bankruptcy	 	 	20	 

ii

 

	 	 	 	 	 	 	 	 	 
	 
	 	10.6	 	Receivers	 	 	20	 
	 
	 	10.7	 	Lien Priority	 	 	20	 
	 
	 	10.8	 	Lawsuits	 	 	20	 
	 
	 	10.9	 	Judgments	 	 	20	 
	 
	 	10.10	 	Death	 	 	20	 
	 
	 	10.11	 	Material Adverse Change	 	 	20	 
	 
	 	10.12	 	Government Action	 	 	21	 
	 
	 	10.13	 	Default Under Related Documents	 	 	21	 
	 
	 	10.14	 	Other Breach Under Agreement	 	 	21	 
	 
	 	 	 	 	 	 	 	 
	11.	 	ENFORCING THIS AGREEMENT; MISCELLANEOUS	 	 	21	 
	 
	 	11.1	 	GAAP	 	 	21	 
	 
	 	11.2	 	Foreign Eligible Accounts Receivable	 	 	21	 
	 
	 	11.3	 	Tennessee Law	 	 	21	 
	 
	 	11.4	 	Successors and Assigns	 	 	21	 
	 
	 	11.5	 	Interest and Loan Charges Not to Exceed Maximum Amounts Allowed by Law	 	 	21	 
	 
	 	11.6	 	Arbitration and Waiver of Jury Trial	 	 	22	 
	 
	 	11.7	 	Severability; Waivers	 	 	23	 
	 
	 	11.8	 	Costs and Attorneys' Fees	 	 	23	 
	 
	 	11.9	 	Individual Liability	 	 	23	 
	 
	 	11.10	 	One Agreement	 	 	23	 
	 
	 	11.11	 	Indemnification	 	 	24	 
	 
	 	11.12	 	Notices	 	 	24	 
	 
	 	11.13	 	Headings	 	 	24	 
	 
	 	11.14	 	Counterparts	 	 	24	 
	 
	 	11.15	 	Prior Agreement Superseded	 	 	24	 

iii

 

SECOND AMENDED AND RESTATED LOAN AGREEMENT

          THIS SECOND AMENDED AND RESTATED LOAN AGREEMENT (the “Agreement”) dated as of April 6,
2006, is between BANK OF AMERICA, N.A., a national banking association (the “Bank”) and
CUMBERLAND PHARMACEUTICALS, INC., a Tennessee corporation (the “Borrower”).

          WHEREAS, the Borrower and the Bank are parties to a certain Amended and Restated Loan
Agreement dated as of October 21, 2003 (the “Existing Loan Agreement”) and certain loan
documents listed on Schedule 1 hereto (the “Existing Loan Documents”);

          WHEREAS, at the Borrower’s request and in reliance upon the representations and inducements of
the Borrower set forth herein, the Bank has agreed to modify the terms and conditions of the
Existing Loan Agreement and to amend and restate the Existing Loan Agreement in its entirety as
more particularly hereinafter set forth; and

          WHEREAS, the Borrower and the Bank have agreed to amend or to amend and restate the Existing
Loan Documents pursuant to the Loan Documents (as hereinafter defined);

          NOW, THEREFORE, in consideration of the Facility No. 1 Commitment and the Facility No. 2
Commitment described below, the mutual covenants and agreements contained herein, and intending to
be legally bound hereby, the Bank and the Borrower agree as follows:

	1.	 	FACILITY NO. 1: LINE OF CREDIT AMOUNT AND TERMS
	 
	1.1	 	Line of Credit Amount.
	 
	(a)	 	Subject to Section 1.2 below, the Bank will provide a line of credit to the Borrower.
The amount of the line of credit (the “Facility No. 1 Commitment”) is Four Million
Dollars ($4,000,000).
	 
	(b)	 	This is a revolving line of credit. During the availability period, the Borrower may repay
principal amounts and reborrow them, provided, however, on the date of this Agreement,
Borrower shall borrow no more than $2,000,000 in the aggregate pursuant to the Facility No. 1
Commitment.
	 
	(c)	 	The Borrower agrees not to permit the principal balance outstanding to exceed the amount of
the Facility No. 1 Commitment. If the Borrower exceeds this limit, the Borrower will
immediately pay the excess to the Bank upon the Bank’s demand.
	 
	1.2	 	Availability Period.

The maximum availability under the Facility No. 1 Commitment shall be $1,500,000 from and after the
date of this Agreement until the earlier of (a) receipt by the Bank of a full appraisal by an
independent party, in form and substance acceptable to the Bank in its sole discretion,
establishing a valuation of the Acetadote product of at least $9,000,000 or (b) receipt by the Bank
of evidence satisfactory to the Bank that the Borrower is in compliance with the Funded Debt to
EBITDA ratio requirement calculated as of September 30, 2006 pursuant to Section 8.3.
Thereafter, the maximum availability under the Facility No. 1 Commitment shall be $4,000,000 until
the second (2nd) anniversary of the date of this Agreement, or such earlier date as the
availability may terminate as provided in this Agreement (the “Facility No. 1 Expiration
Date”).

	1.3	 	Borrowing Base.
	 
	(a)	 	The aggregate principal amount of all amounts from time to time advanced hereunder in respect
of the Facility No. 1 Commitment shall not exceed the Maximum Amount. “Maximum Amount”
shall mean the lesser of the amount of the Facility No. 1 Commitment or the Borrowing Base.

 

 

	 	 	The “Borrowing Base” at any time shall be equal to 80% of Eligible Accounts
Receivable plus 50% of the value of Eligible Inventory.
	 
	(b)	 	As used herein, the following terms shall have the following meanings

	 	(i)	 	“Eligible Accounts Receivable” shall mean all Accounts Receivable of
the Borrower that have been created in the ordinary course of the Borrower’s business
and upon which the Borrower’s right to receive payment is absolute and not contingent
upon the fulfillment of any condition whatsoever. The term “Eligible Accounts
Receivable” shall not include:

	 	(A)	 	any account that is unpaid more than 90 days from the invoice
date thereof;
	 
	 	(B)	 	any account from any Customer who has had an account past due
more than 90 days from the invoice date thereof on two or more occasions
(except with respect to any account for which the Borrower has provided
extended payment terms);
	 
	 	(C)	 	any account for which there exists a right of setoff or,
defense;
	 
	 	(D)	 	any account with respect to which the Customer is either (i)
the United States of America or any department, agency or instrumentality
thereof (excluding accounts with respect to which the Borrower has complied, to
the satisfaction of the Bank, with the Assignment of Claims Act, 31 U.S.C. §
3727), or (ii) any state within the United States of America (excluding
accounts owed by a state that does not have a counterpart to the Assignment of
Claims Act);
	 
	 	(E)	 	any account that arises out of a contract or order that, by its
terms, forbids or makes void or unenforceable any assignment by the Borrower to
the Bank of the account receivable arising with respect thereto;
	 
	 	(F)	 	any account arising from a “sale on approval,” “sale or
return,” “consignment,” or subject to any other repurchase or return agreement;
	 
	 	(G)	 	any account that represents an obligation of a Customer that is
not a resident of the United States or Canada, unless such account is supported
by a letter of credit or other security in form and substance acceptable to the
Bank;
	 
	 	(H)	 	any account that arises from the sale or lease to or
performance of services for, or represents an obligation of, an employee,
affiliate, partner, parent or subsidiary of the Borrower (excluding accounts
with the State of Tennessee, Vanderbilt University, Cardinal, Ranbaxy, Mylan,
Johnson & Johnson, Bioniche, Mayne/Faulding, Amerisource Bergen and McKesson);
	 
	 	(I)	 	any accounts arising from sales of goods or services in which
the performance of the Borrower has been bonded;
	 
	 	(J)	 	any account on which the Bank is not or does not continue to
be, in the Bank’s sole discretion, satisfied with the credit standing of the
customer of the Borrower in relation to the amount of credit extended;
	 
	 	(K)	 	any returns, allowances, rebates, credits and contra items; or
	 
	 	(L)	 	any account of a Customer if 25% or more of the accounts of
such Customer are not eligible pursuant to the criteria set forth in
subsections (A)-(K) above;

2

 

	 	(ii)	 	“Eligible Inventory” shall mean all of the Borrower’s inventory of
CeraLyte, Acetadote and Kristalose® other than (A) work in process and supplies; (B)
all inventory in which the Bank does not have a first priority perfected security
interest; (C) inventory on consignment; (D) repossessed inventory; (E) obsolete
inventory; (F) inventory that is not in good condition or that fails to meet government
standards; and (G) inventory that the Bank in its sole discretion determines to be
ineligible. Inventory will be valued based on book value. As used herein, the term
“book value” shall mean the costs incurred by the Borrower in purchasing and/or
manufacturing its inventory of CeraLyte, Acetadote and Kristalose®.
	 
	 	(iii)	 	“Customers” shall mean the account debtors obligated on the Borrower’s
Accounts Receivable.
	 
	 	(iv)	 	“Accounts Receivable” shall mean all of the Borrower’s accounts,
instruments, contract rights, chattel paper, documents and general intangibles arising
from the sale of goods and/or the rendition of services by the Borrower in the ordinary
course of business, and the proceeds thereof and all security and guaranties therefor,
whether now existing or hereafter created, and all returned, reclaimed or repossessed
goods, and all books and records pertaining to the foregoing. For purposes of
calculating the Borrowing Base hereunder, the actual amounts due from Customers shall
be used regardless of whether the Borrower has granted any Customer a discounted price
with respect to any Account Receivable.

	(c)	 	The amounts of advances under the Facility No. 1 Commitment shall be determined in the sole
discretion of the Bank consistent with the value of the Eligible Accounts Receivable and the
Eligible Inventory, taking into account all fluctuations of the value thereof in light of the
Bank’s experience and sound business principles. The Bank shall be under no obligation to make
any advance to the Borrower under the Facility No. 1 Commitment in excess of the limitations
stated above.
	 
	(d)	 	The Bank and the Borrower shall establish and maintain one or more special lock box or
blocked accounts for the collection of the Accounts Receivable. Each such special account
shall be with the Bank and shall be subject to the Bank’s standard form agreement. Any checks
or other remittances against Accounts Receivables that are received by the Borrower shall be
held in trust for the Bank and turned over by the Borrower to the Bank or to a person
designated by the Bank in the identical form received (except for any necessary endorsement)
as speedily as possible.
	 
	1.4	 	Interest Rate.
	 
	(a)	 	The interest rate is a rate per year equal to the BBA LIBOR
Daily Floating Rate plus 2.50 percentage point(s); provided, however, that in no event shall the
interest payable in respect of amounts advanced pursuant to the Facility No. 1 Commitment
exceed the maximum amounts collectible under applicable law from time to time.
	 
	(b)	 	The BBA LIBOR Daily Floating Rate is a fluctuating rate of
interest equal to the rate per annum equal to the rate per annum
equal to the British Bankers Association LIBOR Rate (“BBA
LIBOR”),
as published by Reuters (or other commercially available source
providing quotations of BBA LIBOR as selected by the Bank from time to time) as determined for each banking day at approximately
11:00 a.m. London time two (2) London Banking Days prior to the date in question, for U.S.
Dollar deposits (for delivery on the first day of such interest period) with a one month term,
as adjusted from time to time in the Bank’s sole discretion for reserve requirements, deposit
insurance assessment rates and other regulatory costs. If such rate is not available at such
time for any reason, then the rate for that interest period will be determined by such
alternate method as reasonably selected by the Bank. A “London Banking Day” is a day
on which banks in London are open for business and dealing in offshore dollars.

3

 

	1.5	 	Repayment Terms.
	 
	(a)	 	The Borrower will pay interest on July 1, 2006 and on the first day of each October, January,
April and July thereafter until payment in full of any principal outstanding under this
facility.
	 
	(b)	 	The Borrower will repay in full any principal, interest or other charges outstanding under
this facility no later than the Facility No. 1 Expiration Date.
	 
	(c)	 	The Borrower may prepay this loan in full or in part at any time. The prepayment will be
applied to the most remote payment of principal due under this Agreement in respect of the
Facility No. 1 Commitment.
	 
	(d)	 	In the event the aggregate principal outstanding balance of advances under the Facility No. 1
Commitment exceed the Maximum Amount at any time, the Borrower shall immediately and without
notice or demand of any kind make such payments as shall be necessary to reduce the principal
balance of the Facility No. 1 Commitment below the Maximum Amount.
	 
	2.	 	FACILITY NO. 2: FIXED RATE TERM LOAN AMOUNT AND TERMS
	 
	2.1	 	Loan Amount.

The Bank agrees to provide a term loan to the Borrower in the amount of Five Million Five Hundred
Thousand Dollars ($5,500,000.00) (the “Facility No. 2 Commitment”).

	2.2	 	Availability Period.
	 
	 	 	The loan is available in one disbursement from the Bank on the date of this Agreement.
	 
	2.3	 	Interest Rate.
	 
	(a)	 	The interest rate is a rate per year equal to the BBA LIBOR
Daily Floating Rate plus 2.50 percentage point(s); provided, however, that in no event
shall the interest payable in respect of amounts advanced pursuant to the Facility No. 2
Commitment exceed the maximum amounts collectible under applicable law from time to time.
	 
	(b)	 	The BBA LIBOR Daily Floating Rate is a fluctuating rate of
interest equal to the rate per annum equal to the rate per annum
equal to the British Bankers Association LIBOR Rate (“BBA
LIBOR”),
as published by Reuters (or other commercially available source
providing quotations of BBA LIBOR as selected by the Bank from time to time) as determined for each banking day at approximately
11:00 a.m. London time two (2) London Banking Days prior to the date in question, for U.S.
Dollar deposits (for delivery on the first day of such interest period) with a one month term,
as adjusted from time to time in the Bank’s sole discretion for reserve requirements, deposit
insurance assessment rates and other regulatory costs. If such rate is not available at such
time for any reason, then the rate for that interest period will be determined by such
alternate method as reasonably selected by the Bank. A “London Banking Day” is a day
on which banks in London are open for business and dealing in offshore dollars.
	 
	2.4	 	Repayment Terms.
	 
	(a)	 	The Borrower will pay interest on July 1, 2006 and on the first day of each October, January,
April and July thereafter until payment in full of any principal outstanding under this
facility.
	 
	(b)	 	The Borrower will repay principal in equal installments of Four Hundred Fifty-Eight Thousand
Three Hundred Thirty-Four and No/00ths Dollars ($458,334.00) beginning on July 1, 2006 and
continuing on the first day of each October, January, April and July thereafter until the
third (3rd) anniversary of the date of this Agreement (the “Repayment Period”). In any
event, on the last day of the Repayment Period, the Borrower will repay the entire remaining
principal balance plus any interest or other charges outstanding under this facility.

4

 

	2.5	 	Prepayments.

The Borrower may prepay this loan in full or in part at any time. The Borrower will give the Bank
irrevocable written notice of the Borrower’s intention to make the prepayment, specifying the date
and amount of the prepayment. The notice must be received by the Bank at least five (5) banking
days in advance of the prepayment. The prepayment will be applied to the most remote payment of
principal due under this Agreement in respect of the Facility No. 2 Commitment.

	3.	 	FEES AND EXPENSES
	 
	3.1	 	Fees.
	 
	(a)	 	Loan Fee. The Borrower agrees to pay a loan fee in the amount of [***]. This fee is
due on the date of this Agreement.
	 
	(b)	 	Warrant. The Borrower agrees to issue to the Bank, a warrant (or an amendment to the
Bank’s existing warrant) to purchase 1,979 shares of common stock of the Borrower to be valued
on the date of this Agreement at [***] (the “Warrant”). This Warrant is to be issued
on the date this Agreement.
	 
	(c)	 	Unused Commitment Fee. The Borrower agrees to pay a fee on any difference between the
availability of the Facility No. 1 Commitment (as determined in accordance with Section
1.2 hereof) and the amount of credit it actually uses, determined by the average of the
daily amount of credit outstanding during the specified period. The
fee will be calculated at 0.50% per year. The fee is due on July 1, 2006 and on the first day of each October, January,
April and July thereafter until the expiration of the availability period.
	 
	3.2	 	Expenses.

The Borrower agrees to immediately repay the Bank for expenses that include, but are not limited
to, filing, recording and search fees, appraisal fees, title report fees and documentation fees.

	3.3	 	Reimbursement Costs.
	 
	(a)	 	The Borrower agrees to reimburse the Bank for any expenses it incurs in the preparation of
this Agreement and any agreement or instrument required by this Agreement. Expenses include,
but are not limited to, reasonable attorneys’ fees, including any allocated costs of the
Bank’s in-house counsel to the extent permitted by applicable law.
	 
	(b)	 	The Borrower agrees to reimburse the Bank for the cost of periodic field examinations of the
Borrower’s books, records and collateral, and appraisals of the collateral, at such intervals
as the Bank may reasonably require, but no less frequently than annually. The actions
described in this paragraph may be performed by employees of the Bank or by independent
appraisers.
	 
	4.	 	COLLATERAL
	 
	4.1	 	Personal Property.

The personal property listed below now owned or owned in the future by the parties listed below
will secure the Borrower’s obligations to the Bank under this Agreement as indicated in the
security agreement. The collateral is further defined in security agreement(s) executed by the
owners of the collateral. In addition, all personal property collateral owned by the Borrower
securing this Agreement shall also secure all other present and future obligations of the Borrower
to the Bank (excluding any consumer credit covered by the federal Truth in Lending law, unless the
Borrower has otherwise agreed in writing or received written notice thereof). All personal property
collateral securing any other present or future obligations of the Borrower to the Bank shall also
secure this Agreement.

	(a)	 	Equipment and fixtures owned by the Borrower.

5

 

	(b)	 	Inventory owned by the Borrower.
	 
	(c)	 	Receivables owned by the Borrower.
	 
	(d)	 	Securities or other investment property owned by the Borrower as described in one or more
pledge agreements required by the Bank.
	 
	(e)	 	Regulation U of the Board of Governors of the Federal Reserve System places certain
restrictions on loans secured by margin stock (as defined in the Regulation). The Bank and the
Borrower shall comply with Regulation U. If any of the collateral is margin stock, the
Borrower shall provide to the Bank a Form U-1 Purpose Statement.
	 
	(f)	 	Deposit accounts with the Bank and owned by the Borrower.
	 
	(g)	 	Patents, trademarks and other general intangibles owned by the Borrower.
	 
	(h)	 	The CET Pledged Note and the CET Security Agreement (as hereinafter defined).
	 
	5.	 	DISBURSEMENTS, PAYMENTS AND COSTS
	 
	5.1	 	Disbursements and Payments.
	 
	(a)	 	Each payment by the Borrower will be made in U.S. Dollars and immediately available funds by
direct debit to a deposit account as specified below or, for payments not required to be made
by direct debit, by mail to the address shown on the Borrower’s statement or at one of the
Bank’s banking centers in the United States.
	 
	(b)	 	Each disbursement by the Bank and each payment by the Borrower will be evidenced by records
kept by the Bank. In addition, the Bank may, at its discretion, require the Borrower to sign
one or more promissory notes.
	 
	5.2	 	Telephone and Telefax Authorization.
	 
	(a)	 	The Bank may honor telephone or telefax instructions for advances or repayments given, or
purported to be given, by any one of the individuals authorized to sign loan agreements on
behalf of the Borrower or any other individual designated by any one of such authorized
signers.
	 
	(b)	 	Advances will be deposited in and repayments will be withdrawn from account number 3782867788
owned by the Borrower, or such other of the Borrower’s accounts with the Bank as designated in
writing by the Borrower.
	 
	(c)	 	The Borrower will indemnify and hold the Bank harmless from all liability, loss, and costs in
connection with any act resulting from telephone or telefax instructions the Bank reasonably
believes are made by any individual authorized by the Borrower to give such instructions. This
paragraph will survive this Agreement’s termination, and will benefit the Bank and its
officers, employees, and agents.
	 
	5.3	 	Direct Debit (Pre-Billing).
	 
	(a)	 	The Borrower agrees that the Bank will debit account number 3782867788 owned by the Borrower,
or such other of the Borrower’s accounts with the Bank as designated in writing by the
Borrower (the “Designated Account”) on the date each payment of principal and interest
and any fees from the Borrower becomes due (the “Due Date”).
	 
	(b)	 	Prior to each Due Date, the Bank will mail to the Borrower a statement of the amounts that
will be due on that Due Date (the “Billed Amount”). The bill will be mailed a specified number of
calendar days prior to

6

 

	 	 	the Due Date, which number of days will be mutually agreed from time
to time by the Bank and the Borrower. The calculations in the bill will be made on the
assumption that no new extensions of credit or payments will be made between the date of the
billing statement and the Due Date, and that there will be no changes in the applicable
interest rate.
	 
	(c)	 	The Bank will debit the Designated Account for the Billed Amount, regardless of the actual
amount due on that date (the “Accrued Amount”). If the Billed Amount debited to the
Designated Account differs from the Accrued Amount, the discrepancy will be treated as
follows:

	 	(i)	 	If the Billed Amount is less than the Accrued Amount, the Billed Amount for the
following Due Date will be increased by the amount of the discrepancy. The Borrower
will not be in default by reason of any such discrepancy.
	 
	 	(ii)	 	If the Billed Amount is more than the Accrued Amount, the Billed Amount for the
following Due Date will be decreased by the amount of the discrepancy.

	 	 	Regardless of any such discrepancy, interest will continue to accrue based on the actual
amount of principal outstanding without compounding. The Bank will not pay the Borrower
interest on any overpayment.
	 
	(d)	 	The Borrower will maintain sufficient funds in the Designated Account to cover each debit. If
there are insufficient funds in the Designated Account on the date the Bank enters any debit
authorized by this Agreement, the Bank may reverse the debit.
	 
	5.4	 	Banking Days.

Unless otherwise provided in this Agreement, a banking day is a day other than a Saturday, Sunday
or other day on which commercial banks are authorized to close, or are in fact closed, in the state
where the Bank’s lending office is located, and, if such day relates to amounts bearing interest at
an offshore rate (if any), means any such day on which dealings in dollar deposits are conducted
among banks in the offshore dollar interbank market. All payments and disbursements that would be
due on a day that is not a banking day will be due on the next banking day. All payments received
on a day that is not a banking day will be applied to the credit on the next banking day.

	5.5	 	Interest Calculation.

Except as otherwise stated in this Agreement, all interest and fees, if any, will be computed on
the basis of a 360-day year and the actual number of days elapsed. This results in more interest or
a higher fee than if a 365-day year is used. Installments of principal that are not paid when due
under this Agreement shall continue to bear interest until paid.

	5.6	 	Default Rate.

Upon the occurrence of any default or after maturity or after judgment has been rendered on any
obligation under this Agreement, all amounts outstanding under this Agreement, including any
interest, fees, or costs that are not paid when due, will at the option of the Bank bear interest
at a rate that is four percentage points (4.00%) higher than the rate of interest otherwise
provided under this Agreement. This may result in compounding of interest. This will not constitute
a waiver of any default.

	6.	 	CONDITIONS

Before the Bank is required to extend any credit to the Borrower under this Agreement, it must
receive any documents and other items it may reasonably require, in form and content acceptable to
the Bank, including any items specifically listed below.

7

 

	6.1	 	Authorizations and Incumbency.

If the Borrower is anything other than a natural person, evidence that the execution, delivery and
performance by the Borrower of this Agreement and any instrument or agreement required under this
Agreement have been duly authorized. A certificate of the secretary of the Borrower as to the
incumbency and signature of all officers of such Borrower authorized to execute or attest to any
instrument or agreement required under this Agreement.

	6.2	 	Governing Documents.

If required by the Bank, a copy of the Borrower’s organizational documents.

	6.3	 	CET Intercompany Debt.

Signed original Promissory Note executed by Cumberland Emerging Technologies, Inc. (“CET”)
and payable to the order of the Borrower, in the maximum principal amount of $856,000 evidencing
the now existing and hereafter arising indebtedness of CET to the Borrower and endorsed in blank by
the Borrower (together with any and all modifications, extensions and renewals thereof, the
“CET Pledged Note”). A signed security agreement by and between CET and Borrower, wherein
CET granted Borrower a first priority security interest in CET’s property described therein, such
security agreement to be in form and substance satisfactory to the Bank (as the same may be
amended, restated, supplemented, extended, modified, restructured, renewed or replaced from time to
time, the “CET Security Agreement”). An assignment to the Bank to be of, and grant to the
Bank of a security interest in, all of the Borrower’s right, title an interest in and to the CET
Pledged Note and the CET Security Agreement, such assignment to be in form and substance
satisfactory to the Bank.

	6.4	 	Security Agreements.

Signed original security agreements, including intellectual property security agreements, covering
the personal property collateral that the Bank requires. Such security agreements, together with
this Agreement, any notes, any warrants and all other instruments, documents and agreements for
time to time evidencing, securing or otherwise relating to the Facility No. 1 Commitment and the
Facility No. 2 Commitment are hereinafter referred to as the “Loan Documents”.

	6.5	 	Perfection and Evidence of Priority.

Evidence that the security interests and liens in favor of the Bank are valid, enforceable,
properly perfected in a manner acceptable to the Bank and prior to all others’ rights and
interests, except those the Bank consents to in writing.

	6.6	 	Payment of Fees.

Payment of all fees and other amounts due and owing to the Bank, including without limitation
payment of all accrued and unpaid expenses incurred by the Bank as required by the paragraph
entitled “Reimbursement Costs.”

	6.7	 	Good Standing.

Certificates of good standing for the Borrower and CET from its state of formation and from any
other state in which the Borrower and CET is required to qualify to conduct its business.

	6.8	 	Legal Opinion.

A written opinion from the Borrower’s and CET’s legal counsel, covering such matters as the Bank
may require. The legal counsel and the terms of the opinion must be acceptable to the Bank.

	6.9	 	Warrant.

Signed original Warrant, duly and validly executed by the Borrower for the benefit of the Bank.

8

 

	6.10	 	Financial Statements.
	 
	(a)	 	Detailed consolidated projections (including balance sheet, profit and loss statement and
statement of cash flow) by product line (i) on a quarterly basis for fiscal year 2006 and (ii)
on an annual basis for fiscal years 2007 and 2008.
	 
	(b)	 	Marketing analysis for Kristalose®, including sales and marketing expense, in form and
substance acceptable to the Bank in its sole discretion.
	 
	6.11	 	Insurance.

Evidence of insurance coverage, as required in the “Covenants” section of this Agreement.

	6.12	 	Product Agreements.
	 
	(a)	 	Receipt and approval by the Bank of the term sheet, the distribution agreement, and other
agreements relating to the Borrower’s purchase of exclusive rights to distribute Kristalose®
in North America, each of which shall be in form and substance acceptable to the Bank in its
sole discretion.
	 
	(b)	 	Receipt by the Bank of all CeraLyte agreements, each of which shall be in form and substance
acceptable to the Bank in its sole discretion.
	 
	(c)	 	Receipt by the Bank of all Procto-Kit agreements, each of which shall be in form and
substance acceptable to the Bank in its sole discretion.
	 
	6.13	 	Consents, Licenses, Permits, Assignments.
	 
	(a)	 	Evidence satisfactory to the Bank that the Borrower has obtained all requisite consents and
approvals required to be obtained from any person to permit the transactions contemplated by
this Agreement and the other Loan Documents executed in connection herewith to be consummated
in accordance with their respective terms and conditions.
	 
	(b)	 	Evidence satisfactory to the Bank that Borrower and the collateral securing this Agreement
are in compliance with all applicable governmental requirements and that all permits, and any
necessary licenses and approvals have been obtained.
	 
	(c)	 	Evidence satisfactory to the Bank that Leo Pavliv has assigned to the Borrower the patent
rights to the pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid.
	 
	6.14	 	Availability.

Evidence satisfactory to the Bank that the Borrower has a minimum liquidity of $2,000,000 in either
cash or available credit under this Agreement.

	6.15	 	Representations, Warranties and No Default.

Receipt by the Bank of a certificate of a properly authorized officer of the Borrower, stating that
(a) each of the representations and warranties contained herein is true and correct at and as of
the date hereof with the same force and effect as if made on such date and (b) no default hereunder
or under any of the other Loan Documents executed in connection therewith has occurred and is
continuing.

	6.16	 	Other Required Documentation.

All other documents, instruments, agreements, opinions, certificates, insurance policies, consents
and evidences of other legal matters, in form and substance satisfactory to the Bank and its
counsel, that are required by the terms of

9

 

any term sheet or commitment of the Bank relating to the
credit that is the subject of this Agreement or that the Bank otherwise may reasonable request.

	7.	 	REPRESENTATIONS AND WARRANTIES

When the Borrower signs this Agreement, and until the Bank is repaid in full, the Borrower makes
the following representations and warranties. Each request for an extension of credit constitutes a
renewal of these representations and warranties as of the date of the request:

	7.1	 	Formation.

If the Borrower is anything other than a natural person, it is duly formed and existing under the
laws of the state or other jurisdiction where organized.

	7.2	 	Authorization.

This Agreement, and any instrument or agreement required hereunder, are within the Borrower’s
powers, have been duly authorized, and do not conflict with any of its organizational papers.

	7.3	 	Enforceable Agreement.

This Agreement is a legal, valid and binding agreement of the Borrower, enforceable against the
Borrower in accordance with its terms, and any instrument or agreement required hereunder, when
executed and delivered, will be similarly legal, valid, binding, and enforceable.

	7.4	 	Good Standing.

In each state in which the Borrower does business, it is properly licensed, in good standing, and,
where required, in compliance with fictitious name statutes.

	7.5	 	No Conflicts.

This Agreement does not conflict with any law, agreement, or obligation by which the Borrower is
bound.

	7.6	 	Financial Information.

All financial and other information that has been or will be supplied to the Bank is sufficiently
complete to give the Bank accurate knowledge of the Borrower’s (and CET’s) financial condition,
including all material contingent liabilities. Since the date of the most recent financial
statement provided to the Bank, there has been no material adverse change in the business condition
(financial or otherwise), operations, properties or prospects of the Borrower or CET. If the
Borrower is comprised of the trustees of a trust, the foregoing representations shall also pertain
to the trustor(s) of the trust.

	7.7	 	Lawsuits.

There is no lawsuit, tax claim or other dispute pending or threatened against the Borrower that, if
lost, would impair the Borrower’s financial condition or ability to repay the loan, except as have
been disclosed in writing to the Bank.

	7.8	 	Collateral.

All collateral required in this Agreement is owned by the grantor of the security interest free of
any title defects or any liens or interests of others, except (a) those that have been approved by
the Bank in writing and (b) liens securing purchase money debt or indebtedness arising under
capitalized lease obligations permitted by this Agreement; provided, however, that in each case any such liens shall attach only to the specific
item(s) of property or asset(s) financed with such purchase money debt or capitalized lease.

10

 

	7.9	 	Permits, Franchises.

The Borrower possesses all permits, memberships, franchises, contracts, licenses required and all
trademark rights, trade name rights, patent rights, copyrights, and fictitious name rights
necessary to enable it to conduct the business in which it is now engaged.

	7.10	 	Other Obligations.

The Borrower is not in default on any obligation for borrowed money, any purchase money obligation
or any other material lease, commitment, contract, instrument or obligation, except as have been
disclosed in writing to the Bank.

	7.11	 	Tax Matters.

The Borrower has no knowledge of any pending assessments or adjustments of its income tax for any
year and all taxes due have been paid, except as have been disclosed in writing to the Bank.

	7.12	 	No Event of Default.

There is no event that is, or with notice or lapse of time or both would be, a default under this
Agreement.

	7.13	 	Insurance.

The Borrower has obtained, and maintained in effect, the insurance coverage required in the
“Covenants” section of this Agreement.

	7.14	 	Location of Borrower.

The place of business of the Borrower (or, if the Borrower has more than one place of business, its
chief executive office) is located as follows:

Cumberland Pharmaceuticals, Inc.

2525 West End Avenue, Suite 950

Nashville, Tennessee 37203

	7.15	 	Capitalization.

As of December 31, 2005, the authorized capital stock of the Borrower consists of (1) 10,000,000
shares of common stock, no par value per share (“Common Shares”), of which 4,890,149 shares
(the “Outstanding Common Shares”) are issued and outstanding, and (2) 3,000,000 shares of
preferred stock, no par value per share, of which 855,495 shares (the “Outstanding Preferred
Shares”) are issued and outstanding, and (3) under the Borrower’s amended 1999 Stock Option
Plan, 3,950,000 options convertible into Common Shares (“Options”) are authorized for
issuance, with 3,910,867 Options issued and outstanding, of which 3,724,011 Options are fully
vested and exercisable. All of the Outstanding Common Shares are duly authorized, validly issued
and outstanding and fully paid and nonassessable and free of preemptive rights. All of the
Outstanding Preferred Shares are duly authorized, validly issued and outstanding and fully paid and
nonassessable and are convertible into Common Shares.

	7.16	 	Material Adverse Change.

Since December 31, 2004, no material adverse change has occurred on or in (a) the properties,
business, prospects, operations, management or financial condition of the Borrower, or (b) the
ability of the Borrower to perform any of its obligations under this Agreement or the other Loan
Documents to which it is a party.

	8.	 	COVENANTS

The Borrower agrees, so long as credit is available under this Agreement and until the Bank is
repaid in full:

11

 

	8.1	 	Use of Proceeds.
	 
	(a)	 	To use the proceeds of the Facility No. 1 Commitment only for (i) the purchase of the
exclusive rights to distribute the Kristalose® product in North America and for general
operating and working capital expenses and (ii) extensions of credit to CET permitted by this
Agreement.
	 
	(b)	 	To use the proceeds of the Facility No. 2 Commitment only for the purchase of the exclusive
rights to distribute the Kristalose® product in North America and for general operating and
working capital expenses.
	 
	(c)	 	The proceeds of the credit extended under this Loan Agreement may not be used directly or
indirectly to purchase or carry any “margin stock” as that term is defined in Regulation U of
the Board of Governors of the Federal Reserve System, or extend credit to or invest in other
parties for the purpose of purchasing or carrying any such “margin stock,” or to reduce or
retire any indebtedness incurred for such purpose.
	 
	8.2	 	Financial Information and Appraisal.

To provide the following financial information and statements in form and content acceptable to the
Bank, and such additional information as requested by the Bank from time to time:

	(a)	 	Within 150 days of the fiscal year end, the annual financial statements of the Borrower,
which shall include a balance sheet, profit and loss statement and statement of cash flow,
certified and dated by an authorized financial officer. These financial statements must be
audited (with an opinion satisfactory to the Bank) by a certified public accountant acceptable
to the Bank. The statements shall be prepared on a consolidated basis and include unaudited
statements on a consolidating basis.
	 
	(b)	 	Within 60 days of the beginning of each fiscal year of the Borrower, a copy of the Borrower’s
operating and capital expenditure budget for such fiscal year, certified and dated by an
authorized financial officer.
	 
	(c)	 	Within 45 days of the period’s end (including the last period in each fiscal year), quarterly
financial statements of the Borrower, which shall include a balance sheet, profit and loss
statement and statement of cash flow. The profit and loss statement and the statement of cash
flow to be submitted under this subsection shall be presented on a quarterly and a
year-to-date basis, and the balance sheet to be submitted under this subsection shall include
comparisons with the same period for the prior year. These financial statements may be
company-prepared. The statements shall be prepared on a consolidated and consolidating basis.
Such financial statements shall be certified and dated by an authorized financial officer and
set forth (i) the information and computations (in sufficient detail) to establish that the
Borrower is in compliance with all financial covenants at the end of the period covered by the
financial statements then being furnished and (ii) whether there existed as of the date of
such financial statements and whether there exists as of the date of the certificate, any
default under this Agreement and, if any such default exists, specifying the nature thereof
and the action the Borrower is taking and proposes to take with respect thereto. The
compliance certificate shall be substantially in the form attached hereto as Exhibit
A.
	 
	(d)	 	Within 30 days of the period’s end (including the last period in each fiscal year), monthly
financial statements of the Borrower, which shall include a balance sheet, profit and loss
statement and statement of cash flow. The profit and loss statement and the statement of cash
flow to be submitted under this subsection shall be presented on a monthly and a year-to-date
basis, and the balance sheet to be submitted under this subsection shall include comparisons
with the same period for the prior year. These financial statements may be company-prepared.
Such financial statements shall be certified and dated by an authorized financial officer and
set forth (i) the information and computations (in sufficient detail) to establish that the
Borrower is in compliance with all financial covenants at the end of the period covered by the
financial statements then being furnished and (ii) whether there existed as of the date of
such financial statements and whether there exists as of the date of the certificate, any
default under this Agreement and, if any such default exists, specifying the nature thereof and the action the Borrower is
taking and proposes to take with respect thereto. The compliance certificate shall be
substantially in the form attached hereto as Exhibit A.

12

 

	(e)	 	Within 10 days of the period’s end (including the last period in each fiscal year), a monthly
listing of accounts receivable aged from the date of invoice attached to a monthly Borrowing
Base Certificate for (and executed by an authorized financial officer) the Borrower in the
form attached hereto as Exhibit B.
	 
	(f)	 	Within 10 days of receipt or dispatch by the Borrower, copies of any management letters and
correspondence relating to management letters, sent or received by the Borrower to or from the
Borrower’s auditor. If no management letter is prepared, the Bank may, in its discretion,
request a letter from such auditor stating that no deficiencies were noted that would
otherwise be addressed in a management letter.
	 
	(g)	 	Such additional financial information regarding the Borrower, CET, pledgor, accommodation
party or other obligor with respect to the loan as the Bank shall request.
	 
	(h)	 	On or before May 31, 2006, full appraisal of the Acetadote product, in form and substance
acceptable to the Bank in its sole discretion.
	 
	8.3	 	Funded Debt to EBITDA Ratio.

To maintain on a consolidated basis a ratio of Funded Debt to EBITDA not exceeding the ratios
indicated for each period specified below:

	 	 	 
	Period	 	Ratios
	 
	 	 
	From September 30, 2006
through December 31, 2006

	 	4.25:1.0
	 
	 	 
	From January 1, 2007
through March 31, 2007

	 	2.50:1.0
	 
	 	 
	From April 1, 2007 and thereafter

	 	2.25:1.0

“Funded Debt” means all outstanding liabilities for borrowed money and other
interest-bearing liabilities, including current and long term debt, promissory notes, seller notes,
letters of credit, if any, and any obligations guaranteed by the Borrower, less the non-current
portion of Subordinated Liabilities.

“EBITDA” means net income after extraordinary losses and before extraordinary gains, less
income or plus loss from discontinued operations plus interest expense, income taxes, depreciation
and amortization expense. EBITDA will be calculated for the twelve-month period ending with the end
of each reporting period.

“Subordinated Liabilities” means liabilities subordinated to the Borrower’s obligations to
the Bank in a manner acceptable to the Bank in its sole discretion.

This ratio will be calculated at the end of each quarter-annual reporting period for which the Bank
requires financial statements, using the results of the twelve-month period ending with that
reporting period.

	8.4	 	Minimum Fixed Charge Coverage Ratio.

To
maintain on a consolidated basis a Minimum Fixed Charge Coverage
Ratio of at least 1.50:1.0 from
and after June 30, 2006.

13

 

“Minimum Fixed Charge Coverage Ratio” means the ratio of (a) the sum of EBITDA plus lease
expense and rent expense, minus maintenance capital expenditures $50,000 per annum, minus income
taxes, minus dividends, withdrawals and other distributions, to (b) the sum of interest expense,
lease expense, rent expense, scheduled principal payments on term debt and the current portion of
capitalized lease obligations.

This ratio will be calculated at the end of each quarter-annual reporting period for which the Bank
requires financial statements, using the results of the twelve-month period ending with that
reporting period.

	8.5	 	Minimum Net Worth.

To have a
net worth as of the date hereof equal to at least $4,750,000, provided, however, that the
aforesaid net worth requirement shall be reduced by the amount, if any, that Borrower’s 2005 fiscal
year-end net worth is reduced by year-end audit adjustments (but in no event shall such reduction
be in excess of $250,000).

“Net Worth” means the value of total assets (including leaseholds and leasehold
improvements and reserves against assets but excluding goodwill, patents, trademarks, trade names,
organization expense, unamortized debt discount and expense, capitalized or deferred research and
development costs, deferred marketing expenses, and other like intangibles, and monies due from
affiliates, officers, directors, employees, shareholders, members or managers) less total
liabilities, including but not limited to accrued and deferred income taxes.

	8.6	 	Minimum EBITDA.

To
maintain EBITDA of not less than $400,000 from June 30, 2006 until such time as the Bank receives a
full appraisal by an independent party, in form and substance acceptable to the Bank in its sole
discretion, establishing a valuation of the Acetadote product of at
least $9,000,000.

EBITDA will be calculated at the end of each quarter-annual reporting period for which the Bank
requires financial statements, using the results of the twelve-month period ending with that
reporting period.

	8.7	 	Capital Expenditures.

Not to make or incur capital expenditures (including capital lease obligations) in an aggregate
amount in excess of $500,000 during any fiscal year.

	8.8	 	Lease Expenditures.

Not to incur obligations for the leasing of real or personal property requiring payments in an
aggregate amount in excess of $350,000 during any fiscal year.

	8.9	 	Dividends and Distributions.

Not to declare, make or pay any dividends (except dividends paid in capital stock), redemptions of
stock or membership interests, distributions and withdrawals (as applicable) to its owners.

	8.10	 	Bank as Principal Depository.

To maintain the Bank as its principal depository bank, including for the maintenance of business,
cash management, operating and administrative deposit accounts.

	8.11	 	Other Debts.

Not to have outstanding or incur any direct or contingent liabilities or lease obligations (other
than those to the Bank), or become liable for the liabilities of others, without the Bank’s written
consent. This does not prohibit:

	(a)	 	Acquiring services, goods, supplies, or merchandise on normal trade credit.

14

 

	(b)	 	Endorsing negotiable instruments received in the usual course of business.
	 
	(c)	 	Obtaining surety bonds in the usual course of business.
	 
	(d)	 	Liabilities, lines of credit and leases in existence on the date of this Agreement disclosed
in writing to the Bank in the Borrower’s most recent financial statement.
	 
	(e)	 	Purchase money debt and capitalized lease obligations financed by the Borrower through
specific research grants to the Borrower for the development of pharmaceutical products in
connection with such obligations, and other purchase money debt and capitalized lease
obligations in an aggregate principal amount not exceeding $250,000 outstanding at any one
time.
	 
	8.12	 	Other Liens.

Not to create, assume, or allow any security interest or lien (including judicial liens) on
property the Borrower now or later owns, except:

	(a)	 	Liens and security interests in favor of the Bank.
	 
	(b)	 	Liens for taxes not yet due.
	 
	(c)	 	Liens outstanding on the date of this Agreement disclosed in writing to and approved by the
Bank.
	 
	(d)	 	Liens securing purchase money debt or indebtedness arising under capitalized lease
obligations permitted by this Agreement; provided, however, that in each case any such liens
shall attach only to the specific item(s) of property or asset(s) financed with such purchase
money debt or capitalized lease.
	 
	8.13	 	Maintenance of Assets.

Not to sell, assign, lease, transfer or otherwise dispose of any part of the Borrower’s business or
the Borrower’s assets except in the ordinary course of the Borrower’s business.

	8.14	 	Investments.

Not to have any existing, or make any new, investments in any individual or entity, or make any
capital contributions or other transfers of assets to any individual or entity, except for:

	(a)	 	Existing investments in CET (other than advances to CET described in Subsection
8.15(c)) disclosed to the Bank in writing.
	 
	(b)	 	Investments permitted by Section 8.15.
	 
	(c)	 	Investments in any of the following:

	 	(i)	 	certificates of deposit;
	 
	 	(ii)	 	U.S. treasury bills and other obligations of the federal government;
	 
	 	(iii)	 	readily marketable securities (including commercial paper, but excluding
restricted stock and stock subject to the provisions of Rule 144 of the Securities and
Exchange Commission).

	8.15	 	Loans.

Not to make any loans, advances or other extensions of credit to any individual or entity, except
for:

15

 

	(a)	 	Existing extensions of credit disclosed to the Bank in writing prior to the date of this
Agreement.
	 
	(b)	 	Extensions of credit in the nature of accounts receivable or notes receivable arising from
the sale or lease of goods or services in the ordinary course of business to non-affiliated
entities.
	 
	(c)	 	Extensions of credit to CET in an aggregate amount not exceeding Eight Hundred Fifty-Six
Thousand Dollars ($856,000) outstanding at any one time, provided, (i) extensions of credit by
the Borrower to CET from the Facility No. 1 Commitment shall not exceed Three Hundred Fifty
Thousand Dollars ($350,000) outstanding at any one time and (ii) such loans are evidenced by
the CET Pledged Note and secured by the CET Security Agreement.
	 
	(d)	 	Advances to employees for business travel and other expenses incurred in the ordinary course
of business in an aggregate amount not exceeding $100,000 outstanding at any one time.
	 
	8.16	 	Change of Management.

Not to make any substantial change in the present executive or management personnel of the
Borrower. A “substantial change”, as used in this subsection shall include, but not be limited to,
the removal or resignation of A.J. Kazimi as Chief Executive Officer and President of the Borrower,
and/or the removal or resignation of David Lowrance as the Director of Finance and Accounting for
the Borrower.

	8.17	 	Change of Ownership or Control.

Not to cause, permit, or suffer any change in the direct or indirect capital ownership or control
of the Borrower such that any individual, entity or group (as defined in Section 13(d) of the
Securities Exchange Act of 1934) except A.J. Kazimi shall become the owner, directly or indirectly,
beneficially or of record, of shares representing more than 30% of the aggregate ordinary voting
power represented by the issued and outstanding capital stock of the Borrower.

	8.18	 	Additional Negative Covenants.

Not to, without the Bank’s written consent:

	(a)	 	Enter into any consolidation, merger, or other combination, or become a partner in a
partnership, a member of a joint venture, or a member of a limited liability company other
than CET.
	 
	(b)	 	Acquire or purchase a business or its assets.
	 
	(c)	 	Change the general character of the business of the Borrower as conducted on the date of this
Agreement or engage in any business activities substantially different from the Borrower’s
present business.
	 
	(d)	 	Liquidate or dissolve the Borrower’s business.
	 
	8.19	 	Notices to Bank

To promptly notify the Bank in writing of:

	(a)	 	Any lawsuit against the Borrower or CET.
	 
	(b)	 	Any substantial dispute between any governmental authority and the Borrower or CET.
	 
	(c)	 	Any event of default under this Agreement, or any event that, with notice or lapse of time or
both would constitute an event of default.

16

 

	(d)	 	Any material adverse change in the Borrower’s or CET’s business condition (financial or
otherwise), operations, properties or prospects, or ability to repay the credit.
	 
	(e)	 	Any change in the Borrower’s name, legal structure, place of business, or chief executive
office if the Borrower has more than one place of business.
	 
	(f)	 	Any uninsured or partially uninsured loss through fire, theft, liability or property damage
in excess of $25,000.
	 
	8.20	 	Insurance
	 
	(a)	 	General Business Insurance. To maintain insurance satisfactory to the Bank as to
amount, nature and carrier covering property damage (including loss of use and occupancy) to
any of the Borrower’s properties, business interruption insurance, public liability insurance
including coverage for contractual liability, product liability and workers’ compensation, and
any other insurance that is usual for the Borrower’s business. Each policy shall provide for
at least thirty (30) days’ prior notice to the Bank of any cancellation thereof.
	 
	(b)	 	Insurance Covering Collateral. To maintain all-risk property damage insurance
policies covering the tangible property comprising the collateral. Each insurance policy must
be in an amount acceptable to the Bank. The insurance must be issued by an insurance company
acceptable to the Bank and must include a lender’s loss payable endorsement in favor of the
Bank in a form acceptable to the Bank.
	 
	(c)	 	Evidence of Insurance. Upon the request of the Bank, to deliver to the Bank a copy of
each insurance policy, or, if permitted by the Bank, a certificate of insurance listing all
insurance in force.
	 
	(d)	 	Insurance Certificates. On or before May 6, 2006, to deliver to the Bank a copy of
the certificate of property insurance including a lender’s loss payable endorsement in favor
of the Bank in form and substance acceptable to the Bank in its sole discretion.
	 
	8.21	 	Compliance with Laws.

To comply with the laws (including any fictitious or trade name statute), regulations, and orders
of any government body with authority over the Borrower’s business. The Bank shall have no
obligation to make any advance to the Borrower except in compliance with all applicable laws and
regulations and the Borrower shall fully cooperate with the Bank in complying with all such
applicable laws and regulations.

	8.22	 	ERISA Plans.

Promptly during each year, to pay and cause any subsidiaries to pay contributions adequate to meet
at least the minimum funding standards under ERISA with respect to each and every Plan; file each
annual report required to be filed pursuant to ERISA in connection with each Plan for each year;
and notify the Bank within ten (10) days of the occurrence of any Reportable Event that might
constitute grounds for termination of any capital Plan by the Pension Benefit Guaranty Corporation
or for the appointment by the appropriate United States District Court of a trustee to administer
any Plan. “ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time
to time. Capitalized terms in this paragraph shall have the meanings defined within ERISA.

	8.23	 	Books and Records.

To maintain adequate books and records.

17

 

	8.24	 	Audits.

To allow the Bank and its agents to inspect the Borrower’s properties and examine, audit and make
copies of books and records at any reasonable time. If any of the Borrower’s properties, books or
records are in the possession of a third party, the Borrower authorizes that third party to permit
the Bank or its agents to have access to perform inspections or audits and to respond to the Bank’s
requests for information concerning such properties, books and records.

	8.25	 	Perfection of Liens.

To help the Bank perfect and protect its security interests and liens, and reimburse it for related
costs it incurs to protect its security interests and liens.

	8.26	 	Cooperation.

To take any action reasonably requested by the Bank to carry out the intent of this Agreement.

	8.27	 	Collateral Account Notification and Acknowledgement.

To deliver to the Bank a signed original Collateral Account Notification and Acknowledgement
Agreement covering the personal property collateral in the account(s) described therein, on or
before May 6, 2006 and in form and substance acceptable to the Bank in its sole discretion.

	9.	 	HAZARDOUS SUBSTANCES
	 
	9.1	 	Indemnity Regarding Hazardous Substances.

The Borrower will indemnify and hold harmless the Bank from any loss or liability the Bank incurs
in connection with or as a result of this Agreement, that directly or indirectly arises out of the
use, generation, manufacture, production, storage, release, threatened release, discharge, disposal
or presence of a hazardous substance. This indemnity will apply whether the hazardous substance is
on, under or about the Borrower’s property or operations or property leased to the Borrower. The
indemnity includes but is not limited to attorneys’ fees (including the reasonable estimate of the
allocated cost of in-house counsel and staff). The indemnity extends to the Bank, its parent,
subsidiaries and all of their directors, officers, employees, agents, successors, attorneys and
assigns.

	9.2	 	Compliance Regarding Hazardous Substances.

The Borrower represents and warrants that the Borrower has complied with all current and future
laws, regulations and ordinances or other requirements of any governmental authority relating to or
imposing liability or standards of conduct concerning protection of health or the environment or
hazardous substances.

	9.3	 	Notices Regarding Hazardous Substances.

Until full repayment of the loans made pursuant to this Agreement, the Borrower will promptly
notify the Bank in writing of any threatened or pending investigation of the Borrower or its
operations by any governmental agency under any current or future law, regulation or ordinance
pertaining to any hazardous substance.

	9.4	 	Site Visits, Observations and Testing.

The Bank and its agents and representatives will have the right at any reasonable time, after
giving reasonable notice to the Borrower, to enter and visit any locations where the collateral
securing this Agreement (the “Collateral”) is located for the purposes of observing the
Collateral, taking and removing environmental samples, and conducting tests. The Borrower shall
reimburse the Bank on demand for the costs of any such environmental investigation and testing. The
Bank will make reasonable efforts during any site visit, observation or testing conducted pursuant this

18

 

paragraph to avoid interfering with the Borrower’s use of the Collateral. The Bank is under no
duty to observe the Collateral or to conduct tests, and any such acts by the Bank will be solely
for the purposes of protecting the Bank’s security and preserving the Bank’s rights under this
Agreement. No site visit, observation or testing or any report or findings made as a result thereof
(“Environmental Report”) (i) will result in a waiver of any default of the Borrower; (ii)
impose any liability on the Bank; or (iii) be a representation or warranty of any kind regarding
the Collateral (including its condition or value or compliance with any laws) or the Environmental
Report (including its accuracy or completeness). In the event the Bank has a duty or obligation
under applicable laws, regulations or other requirements to disclose an Environmental Report to the
Borrower or any other party, the Borrower authorizes the Bank to make such a disclosure. The Bank
may also disclose an Environmental Report to any regulatory authority, and to any other parties as
necessary or appropriate in the Bank’s judgment. The Borrower further understands and agrees that
any Environmental Report or other information regarding a site visit, observation or testing that
is disclosed to the Borrower by the Bank or its agents and representatives is to be evaluated
(including any reporting or other disclosure obligations of the Borrower) by the Borrower without
advice or assistance from the Bank.

	9.5	 	Definition of Hazardous Substances.

“Hazardous substances” means any substance, material or waste that is or becomes designated
or regulated as “toxic,” “hazardous,” “pollutant,” or “contaminant” or a similar designation or
regulation under any current or future federal, state or local law (whether under common law,
statute, regulation or otherwise) or judicial or administrative interpretation of such, including
without limitation petroleum or natural gas.

	9.6	 	Continuing Obligation.

The Borrower’s obligations to the Bank under this Article, except the obligation to give notices to
the Bank, shall survive termination of this Agreement and repayment of the Borrower’s obligations
to the Bank under this Agreement.

	10.	 	DEFAULT AND REMEDIES

If any of the following events of default occurs, the Bank may do one or more of the following:
declare the Borrower in default, terminate the Facility No. 1 Commitment and the Facility No. 2
Commitment, stop making any additional credit available to the Borrower, and require the Borrower
to repay its entire debt immediately and without prior notice. If an event that, with notice or the
passage of time, will constitute an event of default has occurred and is continuing, the Bank has
no obligation to make advances or extend additional credit under this Agreement. In addition, if
any event of default occurs, the Bank shall have all rights, powers and remedies available under
any instruments and agreements required by or executed in connection with this Agreement, as well
as all rights and remedies available at law or in equity. If an event of default occurs under the
paragraph entitled “Bankruptcy,” below, with respect to the Borrower, then the entire debt
outstanding under this Agreement will automatically be due immediately.

	10.1	 	Failure to Pay.

The Borrower fails to make a payment under this Agreement when due.

	10.2	 	Other Bank Agreements.

Any default occurs under any other agreement the Borrower (or any Obligor) or any of the Borrower’s
related entities or affiliates (including CET) has with the Bank or any affiliate of the Bank. For
purposes of this Agreement, “Obligor” shall mean any party pledging collateral to the Bank, or, if the Borrower is comprised of
the trustees of a trust, any trustor.

19

 

	10.3	 	Cross-Default.

Any default occurs under any agreement in connection with any credit the Borrower (or any Obligor)
or any of the Borrower’s related entities or affiliates has obtained from anyone else or that the
Borrower (or any Obligor) or any of the Borrower’s related entities or affiliates has guaranteed.

	10.4	 	False Information.

The Borrower or any Obligor has given the Bank materially false or misleading information or
representations.

	10.5	 	Bankruptcy.

The Borrower, any Obligor or any general partner of the Borrower or of any Obligor files a
bankruptcy petition, a bankruptcy petition is filed against any of the foregoing parties, or the
Borrower, any Obligor or any general partner of the Borrower or of any Obligor makes a general
assignment for the benefit of creditors.

	10.6	 	Receivers.

A receiver or similar official is appointed for a substantial portion of the Borrower’s or any
Obligor’s business, or the business is terminated, or, if any Obligor is anything other than a
natural person, such Obligor is liquidated or dissolved.

	10.7	 	Lien Priority.

The Bank fails to have an enforceable first lien (except for any prior liens to which the Bank has
consented in writing) on or security interest in any property given as security for this Agreement.

	10.8	 	Lawsuits.

Any lawsuit or lawsuits are filed on behalf of one or more trade creditors against the Borrower or
any Obligor in excess of any insurance coverage.

	10.9	 	Judgments.

Any judgments or arbitration awards are entered against the Borrower or any Obligor, or the
Borrower or any Obligor enters into any settlement agreements with respect to any litigation or
arbitration, in excess of any insurance coverage.

	10.10	 	Death.

If the Borrower or any Obligor is a natural person, the Borrower or such Obligor dies or becomes
legally incompetent; if the Borrower or any Obligor is a trust, a trustor dies or becomes legally
incompetent; if the Borrower or any Obligor is a partnership, any general partner dies or becomes
legally incompetent.

	10.11	 	Material Adverse Change.

A material adverse change occurs, or is reasonably likely to occur, in the Borrower’s (or any
Obligor’s) business condition (financial or otherwise), operations, properties or prospects, or
ability to repay the credit; or the Bank determines that it is insecure for any other reason.

20

 

	10.12	 	Government Action.

Any government authority takes action that the Bank believes materially adversely affects the
Borrower’s or any Obligor’s financial condition or ability to repay.

	10.13	 	Default Under Related Documents.

Any default occurs under any subordination agreement, security agreement, deed of trust, mortgage,
the CET Pledged Note, the CET Security Agreement or any other document required by or delivered in
connection with this Agreement or any such document is no longer in effect.

	10.14	 	Other Breach Under Agreement.

A default occurs under any other term or condition of this Agreement not specifically referred to
in this Article. This includes any failure by the Borrower (or any other party named in the
Covenants section) to comply with any financial covenants set forth in this Agreement, whether such
failure is evidenced by financial statements delivered to the Bank or is otherwise known to the
Borrower or the Bank.

	11.	 	ENFORCING THIS AGREEMENT; MISCELLANEOUS
	 
	11.1	 	GAAP.

Except as otherwise stated in this Agreement, all financial information provided to the Bank and
all financial covenants will be made under generally accepted accounting principles, consistently
applied.

	11.2	 	Foreign Eligible Accounts Receivable.

In the event the Accounts Receivable of Borrower with respect to Mayne Pharma PTY, Ltd. (a) are in
an amount not less than $100,000 and (b) but for the exclusion in clause (G) of the definition of
“Eligible Accounts Receivable” in Subsection 1.3(b)(i) above, such Accounts Receivable
would otherwise be Eligible Accounts Receivable, then the Borrower and the Bank agree to enter into
negotiations, in good faith, regarding an amendment of the definition of “Eligible Accounts
Receivable” to take into account all or a portion of such Mayne Pharma PTY, Ltd. receivables in a
mutually acceptable manner. Unless and until such an amendment has been approved, executed and
delivered by the Borrower and the Bank, all Eligible Accounts Receivable shall be determined in
accordance with the terms in this Agreement without reference to this Section 11.2 or any
similar understandings between the parties.

	11.3	 	Tennessee Law.

This Agreement is governed by Tennessee law.

	11.4	 	Successors and Assigns.

This Agreement is binding on the Borrower’s and the Bank’s successors and assignees. The Borrower
agrees that it may not assign this Agreement without the Bank’s prior consent. The Bank may sell
participations in or assign this loan, and may exchange information about the Borrower (including,
without limitation, any information regarding any hazardous substances) with actual or potential
participants or assignees. If a participation is sold or the loan is assigned, the purchaser will
have the right of set-off against the Borrower.

	11.5	 	Interest and Loan Charges Not to Exceed Maximum Amounts Allowed by Law.

Anything in this Agreement or any of the other Loan Documents to the contrary notwithstanding, in
no event whatsoever, whether by reason of advancement of proceeds of the loans hereunder,
acceleration of the maturity of the unpaid balance of such loans or otherwise, shall the interest
and loan charges agreed to be paid to the Bank for the use of the money advanced or to be advanced
hereunder exceed the maximum amounts collectible under
applicable laws in effect from time to time. It is understood and agreed by the parties that, if
for any reason whatsoever the interest or loan charges paid or contracted to be paid by the
Borrower in respect of the loans made

21

 

hereunder shall exceed the maximum amounts collectible under
applicable laws in effect from time to time, then ipso facto, the obligation to pay
such interest and/or loan charges shall be reduced to the maximum amounts collectible under
applicable laws in effect from time to time, and any amounts collected by the Bank that exceed such
maximum amounts shall be applied to the reduction of the principal balance of the loans and/or
refunded to the Borrower so that at no time shall the interest or loan charges paid or payable in
respect of the loans hereunder exceed the maximum amounts permitted from time to time by applicable
law.

	11.6	 	Arbitration and Waiver of Jury Trial.
	 
	(a)	 	This paragraph concerns the resolution of any controversies or claims between the parties,
whether arising in contract, tort or by statute, including but not limited to controversies or
claims that arise out of or relate to: (i) this agreement (including any renewals, extensions
or modifications); or (ii) any document related to this agreement (collectively a “Claim”).
For the purposes of this arbitration provision only, the term “parties” shall include any
parent corporation, subsidiary or affiliate of the Bank involved in the servicing, management
or administration of any obligation described or evidenced by this agreement.
	 
	(b)	 	At the request of any party to this agreement, any Claim shall be resolved by binding
arbitration in accordance with the Federal Arbitration Act (Title 9, U.S. Code) (the “Act”).
The Act will apply even though this agreement provides that it is governed by the law of a
specified state. The arbitration will take place on an individual basis without resort to any
form of class action.
	 
	(c)	 	Arbitration proceedings will be determined in accordance with the Act, the then-current rules
and procedures for the arbitration of financial services disputes of the American Arbitration
Association or any successor thereof (“AAA”), and the terms of this paragraph. In the event of
any inconsistency, the terms of this paragraph shall control. If AAA is unwilling or unable to
(i) serve as the provider of arbitration or (ii) enforce any provision of this arbitration
clause, the Bank may designate another arbitration organization with similar procedures to
serve as the provider of arbitration.
	 
	(d)	 	The arbitration shall be administered by AAA and conducted, unless otherwise required by law,
in any U.S. state where real or tangible personal property collateral for this credit is
located or if there is no such collateral, in the state specified in the governing law section
of this agreement. All Claims shall be determined by one arbitrator; however, if Claims exceed
Five Million Dollars ($5,000,000), upon the request of any party, the Claims shall be decided
by three arbitrators. All arbitration hearings shall commence within ninety (90) days of the
demand for arbitration and close within ninety (90) days of commencement and the award of the
arbitrator(s) shall be issued within thirty (30) days of the close of the hearing. However,
the arbitrator(s), upon a showing of good cause, may extend the commencement of the hearing
for up to an additional sixty (60) days. The arbitrator(s) shall provide a concise written
statement of reasons for the award. The arbitration award may be submitted to any court having
jurisdiction to be confirmed, judgment entered and enforced.
	 
	(e)	 	The arbitrator(s) will give effect to statutes of limitation in determining any Claim and may
dismiss the arbitration on the basis that the Claim is barred. For purposes of the application
of the statute of limitations, the service on AAA under applicable AAA rules of a notice of
Claim is the equivalent of the filing of a lawsuit. Any dispute concerning this arbitration
provision or whether a Claim is arbitrable shall be determined by the arbitrator(s). The
arbitrator(s) shall have the power to award legal fees pursuant to the terms of this
agreement.
	 
	(f)	 	This paragraph does not limit the right of any party to: (i) exercise self-help remedies,
such as but not limited to, setoff; (ii) initiate judicial or non-judicial foreclosure against
any real or personal property collateral; (iii) exercise any judicial or power of sale rights,
or (iv) act in a court of law to obtain an interim remedy, such as but not limited to,
injunctive relief, writ of possession or appointment of a receiver, or additional or
supplementary remedies.

22

 

	(g)	 	The filing of a court action is not intended to constitute a waiver of the right of any
party, including the suing party, thereafter to require submittal of the Claim to arbitration.
	 
	(h)	 	By agreeing to binding arbitration, the parties irrevocably and voluntarily waive any right
they may have to a trial by jury in respect of any Claim. Furthermore, without intending in
any way to limit this agreement to arbitrate, to the extent any Claim is not arbitrated, the
parties irrevocably and voluntarily waive any right they may have to a trial by jury in
respect of such Claim. This provision is a material inducement for the parties entering into
this agreement.
	 
	11.7	 	Severability; Waivers.

If any part of this Agreement is not enforceable, the rest of this Agreement may be enforced. The
Bank retains all rights, even if it makes a loan after default. If the Bank waives a default, it
may enforce a later default. Any consent or waiver under this Agreement must be in writing.

	11.8	 	Costs and Attorneys’ Fees.

The Borrower shall reimburse the Bank for any reasonable costs and attorneys’ fees incurred by the
Bank in connection with the enforcement or preservation of any rights or remedies under this
Agreement and any other documents executed in connection with this Agreement, and in connection
with any amendment, waiver, “workout” or restructuring under this Agreement. In the event of a
lawsuit or arbitration proceeding, the prevailing party is entitled to recover costs and reasonable
attorneys’ fees incurred in connection with the lawsuit or arbitration proceeding, as determined by
the court or arbitrator. In the event that any case is commenced by or against the Borrower under
the Bankruptcy Code (Title 11, United States Code) or any similar or successor statute, the Bank is
entitled to recover costs and reasonable attorneys’ fees incurred by the Bank related to the
preservation, protection, or enforcement of any rights of the Bank in such a case. As used in this
paragraph, “attorneys’ fees” includes the allocated costs of the Bank’s in-house counsel.

	11.9	 	Individual Liability.

If the Borrower is a natural person, the Bank may proceed against the Borrower’s business and
non-business property in enforcing this and other agreements relating to this loan. If the Borrower
is a partnership, the Bank may proceed against the business and non-business property of each
general partner of the Borrower in enforcing this and other agreements relating to this loan.

	11.10	 	One Agreement.

This Agreement, the Loan Documents and any related security or other agreements required by this
Agreement, collectively:

	(a)	 	represent the sum of the understandings and agreements between the Bank and the Borrower
concerning this credit;
	 
	(b)	 	replace any prior oral or written agreements between the Bank and the Borrower concerning
this credit; and
	 
	(c)	 	are intended by the Bank and the Borrower as the final, complete and exclusive statement of
the terms agreed to by them.

In the event of any conflict between this Agreement and any other agreements required by this
Agreement, this Agreement will prevail. Any reference in any related document to a “promissory
note” or a “note” executed by the Borrower and dated as of the date of this Agreement shall be
deemed to refer to this Agreement and any promissory note(s) that may be executed as additional
evidence of the debt hereunder, all as now in effect or as hereafter amended, modified, extended,
renewed or restated.

23

 

	11.11	 	Indemnification.

The Borrower will indemnify and hold the Bank harmless from any loss, liability, damages,
judgments, and costs of any kind relating to or arising directly or indirectly out of (a) this
Agreement or any document required hereunder, (b) any credit extended or committed by the Bank to
the Borrower hereunder, and (c) any litigation or proceeding related to or arising out of this
Agreement, any such document, or any such credit. This indemnity includes but is not limited to
attorneys’ fees (including the allocated cost of in-house counsel). This indemnity extends to the
Bank, its parent, subsidiaries and all of their directors, officers, employees, agents, successors,
attorneys, and assigns. This indemnity will survive repayment of the Borrower’s obligations to the
Bank. All sums due to the Bank hereunder shall be obligations of the Borrower, due and payable
immediately without demand.

	11.12	 	Notices.

Unless otherwise provided in this Agreement or in another agreement between the Bank and the
Borrower, all notices required under this Agreement shall be personally delivered or sent by first
class mail, postage prepaid, or by overnight courier, to the addresses on the signature page of
this Agreement, or sent by facsimile to the fax numbers listed on the signature page, or to such
other addresses as the Bank and the Borrower may specify from time to time in writing. Notices and
other communications shall be effective (i) if mailed, upon the earlier of receipt or five (5) days
after deposit in the U.S. mail, first class, postage prepaid, (ii) if telecopied, when transmitted,
or (iii) if hand-delivered, by courier or otherwise (including telegram, lettergram or mailgram),
when delivered.

	11.13	 	Headings.

Article and paragraph headings are for reference only and shall not affect the interpretation or
meaning of any provisions of this Agreement.

	11.14	 	Counterparts.

This Agreement may be executed in as many counterparts as necessary or convenient, and by the
different parties on separate counterparts each of which, when so executed, shall be deemed an
original but all such counterparts shall constitute but one and the same agreement.

	11.15	 	Prior Agreement Superseded.

This Agreement supersedes the Existing Loan Agreement, and any credit outstanding thereunder shall
be deemed to be outstanding under this Agreement.

[This space left blank intentionally; signature page follows]

24

 

This Agreement is executed as of the date stated at the top of the first page.

	 	 	 	 	 	 	 	 	 
	BANK OF AMERICA, N.A.	 	 	 	CUMBERLAND PHARMACEUTICALS, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Elizabeth L. Knox
	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 	 	 
	Typed Name:

	 	 	 	 	 	Typed Name:	 	 
	 

	 	 
	 	 	 	 	 	 
	Title:
	 	SVP	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Address where notices to the Bank are to be sent:
	 	 	 	Address where notices to the Borrower are to be sent:
	 
	 	 	 	 	 	 	 	 
	Bank of America, N.A.

Bank of America Plaza

414 Union Street

Nashville, TN 37219-1697

Attn: Healthcare Banking Group (TN1-100-04-17)

Facsimile: (615) 749-4951	 	 	 	Cumberland Pharmaceuticals, Inc.

2525 West End Avenue, Suite 950

Nashville, Tennessee 37203

Attn: A.J. Kazimi, Chief Executive Officer

Facsimile No. (615) __-____
	 
	 	 	 	 	 	 	 	 
	ACKNOWLEDGED:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	CUMBERLAND EMERGING TECHNOLOGIES, INC.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Typed Name:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Title:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

25

 

This Agreement is executed as of the date stated at the top of the first page.

	 	 	 	 	 	 	 	 	 
	BANK OF AMERICA, N.A.	 	 	 	CUMBERLAND PHARMACEUTICALS, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	By:
	 	/s/ A.J. Kazimi
	 

	 	 
	 	 	 	 	 	 
	Typed Name:
	 	 	 	 	 	Typed Name:	 	A.J. Kazimi
	 

	 	 
	 	 	 	 	 	 
	Title:
	 	 	 	 	 	Title:	 	C.E.O.
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Address where notices to the Bank are to be sent:	 	 	 	Address where notices to the Borrower are to be sent:
	 
	 	 	 	 	 	 	 	 
	Bank of America, N.A.

Bank of America Plaza

414 Union Street

Nashville, TN 37219-1697

Attn: Healthcare Banking Group (TN1-100-04-17)

Facsimile: (615) 749-4951	 	 	 	Cumberland Pharmaceuticals, Inc.

2525 West End Avenue, Suite 950

Nashville, Tennessee 37203

Attn: A.J. Kazimi, Chief Executive Officer

Facsimile No. (615) 255-0068
	 
	 	 	 	 	 	 	 	 
	ACKNOWLEDGED:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	CUMBERLAND EMERGING TECHNOLOGIES, INC.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ A.J. Kazimi	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Typed Name:

	 	A.J. Kazimi	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Title:

	 	C.E.O.	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

26

 

SCHEDULE 1

Existing Loan Documents

	1.	 	Third Amended and Restated Promissory Note dated March 1, 2005, in the principal amount not
exceeding $3,500,000.00, made and executed by Borrower and payable to the order of Bank.
	 
	2.	 	Trademark and Patent Security Agreement dated April 19, 2002, between Borrower and Bank, as
amended by that certain First Amendment to Trademark and Patent Security Agreement dated
August 1, 2002.
	 
	3.	 	Security Agreement dated April 19, 2002, between Borrower and Bank, as amended by that
certain First Amendment to Security Agreement dated August 1, 2002.

27

 

EXHIBIT A

COMPLIANCE CERTIFICATE

     This Compliance Certificate is delivered pursuant to Section 8.2 of that certain Loan
Agreement dated as of April 6, 2006 (together with all amendments and modifications, if any, from
time to time made thereto, the “Loan Agreement”), between Cumberland Pharmaceuticals, Inc.,
a Tennessee corporation (the “Borrower”) and Bank of America, N.A. (the “Bank”).
Unless otherwise defined, terms used herein (including the attachments hereto) have the meanings
provided in the Loan Agreement.

     The undersigned, being the duly elected, qualified and acting                      of the Borrower, on
behalf of the Borrower and solely in his or her capacity as an officer of the Borrower, hereby
certifies and warrants that:

     1. He or she is the                      of the Borrower and that, as such, he or she is
authorized to execute this certificate on behalf of the Borrower.

     2. As of                                         , 200           :

     (a) The Borrower was not in default of any of the provisions of the Loan
Agreement during the period as to which this Compliance Certificate relates; and

     (b) The financial statements being submitted to the Bank by the Borrower with
this Certificate are true and correct as of the date hereof.

     IN WITNESS WHEREOF, the undersigned has executed and delivered this certificate, this
                     day of                     , 200___.

	 	 	 	 	 
	CUMBERLAND PHARMACEUTICALS, INC.
	 
	 	 	 	 
	By:
	 	 	 	 
	 	 	 
	Typed Name:	 	 
	 

	 	 	 	 
	Title:
	 	 	 	 
	 	 	 

28

 

EXHIBIT B

BORROWING BASE CERTIFICATE

     This Borrowing Base Certificate is delivered pursuant to pursuant to Section 8.2 of that
certain Loan Agreement dated as of April 6, 2006 (together with all other amendments and
modifications, if any, from time to time made thereto, the “Loan Agreement”), between
Cumberland Pharmaceuticals, Inc., a Tennessee corporation (the “Borrower”) and Bank of
America, N.A (the “Bank”). Unless otherwise defined, terms used herein (including the
attachments hereto) have the meanings provided in the Loan Agreement.

     The undersigned, being the duly elected, qualified and acting                      of the Borrower,
on behalf of the Borrower and solely in his or her capacity as an officer of the Borrower, hereby
certifies and warrants that:

     1. He or she is the                      of the Borrower and that, as such, he or she is
authorized to execute this certificate on behalf of the Borrower.

     2. Attached hereto is a true and accurate listing of accounts receivable aged from date
of invoice up through                     , 200          .

     3. Attached hereto is a true and accurate listing of the inventory of the Borrower.

     4. The Borrowing Base as of                     , 200          , as such term is defined under
the Loan Agreement, is $                                        .

     IN WITNESS WHEREOF, the undersigned has executed and delivered this certificate, this
                     day of                     , 200          .

	 	 	 	 	 
	CUMBERLAND PHARMACEUTICALS, INC.
	 
	 	 	 	 
	By:
	 	 	 	 
	 	 	 
	Typed Name:	 	 
	 

	 	 	 	 
	Title:
	 	 	 	 
	 	 	 

29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]